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 Computationally driven drug design/discovery efforts generally rely on accurate 
assessment of the forces that guide the molecular recognition process. HINT 
(Hydropathic INTeraction) is a natural force field, derived from experimentally 
determined partition coefficients that quantifies all non-bonded interactions in the 
biological environment, including hydrogen bonding, electrostatic and hydrophobic 
interactions, and the energy of desolvation. The overall goal of this work is to apply the 
HINT-based atomic level description of molecular systems to biologically important 
 
	   xvi 
 
proteins, to better understand their biochemistry – a key step in exploiting them for 
therapeutic purposes. 
This dissertation discusses the results of three diverse projects: i) structural 
modeling of human sphingosine kinase 2 (SphK2, a novel anticancer target) and 
binding mode determination of an isoform selective thiazolidine-2,4-dione (TZD) analog; 
ii) structural modeling of human cytomegalorvirus (HCMV) alkaline nuclease (AN) UL98 
(a novel antiviral target) and subsequent virtual screening of its active site; and iii) 
explicit treatment of interfacial waters during protein-protein docking process using 
HINT-based computational tools. 
SphK2 is a key regulator of the sphingosine-rheostat, and its upregulation 
/overexpression has been associated with cancer development. We report structural 
modeling studies of a novel TZD-analog that selectively inhibits SphK2, in a HINT 
analysis that identifies the key structural features of ligand and protein binding site 
responsible for isoform selectivity.  
The second aim was to build a three-dimensional structure of a novel HCMV 
target – AN UL98, to identify its catalytically important residues. HINT analysis of the 
interaction of 5’ DNA end at its active site is reported. A parallel aim to perform in silico 
screening with a site-based pharmacophore model, identified several novel hits with 
potentially desirable chemical features for interaction with UL98 AN.   
The majority of current protein-protein docking algorithms fail to account for water 
molecules involved in bridging interactions between partners, mediating and stabilizing 
 
	   xvii 
 
their association. HINT is capable of reproducing the physical and chemical properties 
of such waters, while accounting for their energetic stabilizing contributions. We have 
designed a solvated protein-protein docking protocol that explicitly models the Relevant 
bridging waters, and demonstrate that more accurate results are obtained when water is 
not ignored. 
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CHAPTER 1 
INTRODUCTION 	  	  	  
1.1 The Hydrophobic Effect 
In chemistry, hydrophobicity (coming from Greek words hydro, meaning water, 
and phobos, meaning fear) is the physical property/tendency of a non-polar molecule to 
form aggregates in order to reduce their surface area exposed to a surrounding polar 
environment. This hydrophobic effect affects a number of diverse systems – from 
something as simple as immiscibility of oil in water to more complex phenomenon at the 
molecular level like protein folding and ligand binding.1 Decades of research into 
understanding the biomolecular environment has established the fact that four major 
types of non-covalent interactions – hydrogen bonds, ionic interactions, Van der Waals 
interactions and hydrophobic interactions, govern nearly all processes at the molecular 
level, which is at the core of biological action. 
While a “bond” is definitely not created, Kauzmann coined the term – 
hydrophobic bond, to describe the adhesion tendency of non-polar molecules within an 
aqueous solution.2 Through the mid-twentieth century, the concept of a bond between 
two non-polar molecules was widely accepted, since this attractive force was unusually
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strong. However, with a better understanding of the physical properties of dilute 
solutions of hydrophobic molecules in water, it was recognized that this attraction is a 
more complex phenomenon involving the configurational rearrangement of polar water 
molecules as the two hydrophobic species come together.3 The association/aggregation 
of non-polar molecules due to the hydrophobic effect is energetically favorable due to 
the increase in entropy associated with the release/scattering of ordered water 
molecules surrounding them. The manifestations of the hydrophobic effect have been 
well reviewed in the literature.1,4,5  
 A large number of biological processes like protein folding; absorption, 
distribution, metabolism, and excretion of biological molecules; molecular recognition; 
protein-ligand interactions; protein-protein interactions; and more are governed by 
hydrophobicity. The hydrophobic effect plays a central role in guiding protein structure. 
Water-soluble proteins organize themselves such that amino acids with hydrophobic 
side-chains are retained within the core and buried from water, while amino acids with 
charged and polar side-chains are located on the solvent exposed surface, where they 
are capable of interacting with the surrounding water molecules. The hydrophobic effect 
makes a significantly large contribution towards the stability of globular proteins, and 
together with hydrogen bonding interactions within the core, drives the protein folding 
process.6 The basic physical principles of molecular recognition are governed by 
thermodynamics, especially the Gibbs free energy (Δ𝐺), which is given by –  
 𝚫𝑮 =   𝚫𝑯− 𝑻𝚫𝑺 (1) 
   
described by the sum of changes in enthalpy (ΔH) and entropy (–TΔS) of the system.  
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The hydrophobic effect largely contributes towards the entropic term. Protein-ligand or 
protein-protein binding events involve bringing two molecules together, mainly via 
formation of electrostatic interactions like hydrogen bonds or hydrogen-bonding 
networks formed through water molecules. Those water molecules that are unable to 
locate within the binding interface are displaced into the bulk solvent, increasing entropy 
of the system. 
 For medicinal chemists engaged in drug discovery, the atomistic level 
understanding of how biomolecules associate (both intra- or intermolecular) and the 
precise chemical and physical features responsible for mediating them is of utmost 
importance. Structure-based drug design efforts rely on the knowledge of 3D structure 
of therapeutically relevant biomacromolecules and complexes. On the other hand, 
ligand-based drug design efforts rely only on the knowledge of physicochemical 
properties of small-molecules/ligands that bind to these biological targets of interest. 
These efforts aim to identify and optimize the biomolecular interactions, in search of 
novel, more potent drugs. The following section will review the different types of 
molecular interactions present in a single protein-ligand complex, from the vantage point 
of a medicinal chemist. 
 
 
1.2 Molecular Interactions 
A comprehensive review on the specific types of intermolecular interactions 
between ligands and their host molecules has been described elsewhere,7 and should 
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be referred to for intricate details. Here, we will focus on some of the more frequently 
observed interactions observed in protein-ligand crystal structures. 
One of the most important specific molecular interactions in ligand binding, 
biomacromolecular associations and related phenomenon is hydrogen bonding. Its 
structural and functional role in processes like protein secondary structure stabilization, 
protein folding, molecular recognition, enzymatic reactions, has been well documented.8 
It is a well-accepted fact that hydrogen bonds are primarily electrostatic and highly 
directional in nature.9,10 The prevalence of different types of hydrogen bonding 
interactions within protein structures and in their complexes with ligands, like 
interactions between NH and carbonyl groups; between OH and carbonyl, ether and 
ester groups; and those with aromatic heterocycles; has been studied from crystal 
structure databases.7,11-13 The traditional distance preference, the ‘van der Waals 
distance cutoff’, for identifying a hydrogen bond is too limiting and X–HA interactions 
with median distances between the proton and acceptor atom up to 3.0 Å have been 
observed.14 Also, there are pronounced angular preferences for hydrogen bonds – with 
linear interactions (angles > 150°) preferred, although the location of electron density, 
molecular dipole and other neighboring intermolecular forces may influence the 
geometry to deviate.7 While extremely important in conveying specificity to a recognition 
process, the contribution of hydrogen bonding towards net binding free energy gain is 
minimal in most cases as desolvation of the donor and acceptor atoms must occur for 
the interaction to form, and as a result, the effects of hydration and hydrogen bond 
formation counterbalance each other.15 This also holds true for salt bridges, where the 
hydrogen bond distances are comparatively shorter and the interaction stronger.16 Since 
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hydrogen bonds differ significantly in their intrinsic strengths, Laurence, C. et al. have 
recently introduced the pKBHX scale, the hydrogen-bond basicity scale, to determine the 
relative strength of a hydrogen-bond acceptor.17 This scale is created by measuring the 
equilibrium constant of the reaction of formation of hydrogen bond for a series of bases 
under the same conditions. It provides medicinal chemists a tool to probe the strength of 
a hydrogen bonding interaction systematically in an attempt to design more potent and 
selective analogues.18,19 Other aspects of hydrogen bonds often observed in intra- and 
intermolecular interactions like cooperative hydrogen bonding, referring to additional 
hydrogen bonds in the vicinity that mutually strengthen each other;20 
multicentered/branched hydrogen bonds, referring to the stabilization of a hydrogen 
bond by additional partners to satisfy the hydrogen bonding potential;21 and neighboring 
acceptor and donor groups that might weaken a hydrogen bond;22 also require attention 
of the designer of drugs. 
 Numerous instances of weaker hydrogen bonds, involving non-classical donors 
and acceptors, have been observed in proteins.21 The π-electron cloud of an aromatic 
ring can act as hydrogen bond acceptor to classical amide NH and hydroxyl OH donors, 
as well as hydrogens of aromatic XCH units polarized by neighboring heteroatoms (X = 
O, N).23 Other frequently observed weak hydrogen bonds in crystal structures are 
CFHN and CFHO interactions, the Cα-HO=C interactions, the Cα-HF 
interactions, a SHπ-system interaction, etc.24-27 A different kind of hydrogen bond-like 
interaction is the cation-π interaction. Cations, from small ions like Li+ to complex 
groups like guanidinuim and ammonium, are strongly attracted to π electrons of 
aromatic side-chains of Phe, Tyr, and Trp. Stacking interactions of the guanidino-group 
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of arginine with the aromatic rings of nucleic acid are conserved in some protein-nucleic 
acid complexes. Not just cations, but methyl groups bound to an electronegative atom 
(like alkylammonium group) are also capable of interacting with the π face of aromatic 
rings.28,29 
 Another type of non-covalent interaction observed between protein and ligand is 
the halogen bond. Halogen atoms of small-molecule ligands, when bound to aryl or 
electron withdrawing alkyl groups, show attraction towards carbonyl groups and other 
classical hydrogen-bond acceptors found in proteins, resulting in a C–XB type of 
interaction (X – halogen atom; B – electronegative acceptor atom).30 The strength of a 
halogen bond is highly dependent on a number of things – the size of the halogen atom 
(the larger the halogen atom, the stronger the interaction), the electronegativity of the 
carbon substituent in the C–X partner (the higher the electronegativity, the stronger the 
interaction), and the electron density of the binding partner.31,32 Similar to the cation–π 
interactions, a weak favorable interaction has also been observed between aromatic 
rings and halogen substituents.33 Various groups have performed detailed analyses of 
different interactions involving halogen atoms, with results emphasizing the fact that 
halogens should not be viewed as only lipophilic groups, but can be utilized to form 
electrostatic interactions within the protein binding site under appropriate conditions. 
 One of the most important non-covalent interactions prevalent in almost all 
protein-ligand/protein-protein complexes is the hydrophobic interaction. The formation of 
strong interactions between non-polar ligands and a lipophilic protein pocket, formed by 
side chains of non-polar amino acids like leucine and phenylalanine, can be attributed to 
the hydrophobic effect. Similar to aggregation/micelle formation, a non-polar ligand 
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prefers to bind to a hydrophobic protein pocket resulting in decreased surface area 
exposed to waters, for both the ligand and the protein, and a subsequent gain in 
entropy, thus making the entire process energetically favorable. Hydrophobic 
interactions involving aryl-aryl/aryl-alkyl groups in host and guest molecules are 
facilitated by the electronic properties of the interacting aromatic rings. In case of aryl-
aryl interactions, the aromatic side chains of protein residues interact with aryl rings of 
the ligand in a parallel-displaced stacking arrangement, maximizing overlap of the π-
systems. The stacking arrangement between electron-rich hosts (due to electron-
donating substituents) and complementary electron-deficient guests (due to electron-
withdrawing substituents) affords charge transfer, thereby strengthening the interaction. 
In case of heterocyclic aromatic rings, the orientation of the interaction is controlled by 
the complementary alignment of partial charges on atoms and molecular dipoles.34 In 
contrast to aryl-aryl interactions, the interaction between an alkyl group and an aromatic 
ring is more biased towards an edge-to-face geometry. The interaction energy of this 
type of interaction can be increased with increasing the acidity of the interacting CH unit 
of the alkyl partner.35 Significant binding energy gains can be achieved by promoting 
intermolecular hydrophobic interactions, as evident from various studies showing 
correlation between binding affinity and the amount of hydrophobic surface buried upon 
ligand binding.36 
 Knowledge of the various interactions discussed above leads to better 
understanding of protein-ligand complexes, and draws the attention of a medicinal 
chemist / drug designer to the fact that there are multiple interactions involved in the 
binding process and any particular interaction must not be overemphasized.   
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1.3 Interfacial Structural Waters 
Interfacial waters are not just “spectators” to ligand-binding or protein-protein 
association process; every such event involves displacement of water molecules from 
the binding site. The majority of biomolecular interactions occur in aqueous medium – 
each interacting partner is surrounded by water molecules, and the changes in the 
water structure upon their association contributes significantly towards the entropic 
component of the Gibbs free energy. Also, due to its high polarity, the presence of water 
molecules significantly changes the electrostatic interactions at the binding interface, 
and thereby contributes towards the enthalpic component too. Although having just 
three atoms, a single water molecule can engage in four hydrogen bonds (two as donor 
and two as acceptor). This enables water to mediate binding between protein and its 
ligand (both small-molecules and other proteins) via a hydrogen-bonding network.37 In 
fact, analysis of thousands of protein-ligand crystal structures has revealed the 
presence of at least one water-mediated bridging interaction in each binding site.38 
Detailed analysis of the interface of protein complexes has shown that 40.1% of 
interfacial residues interact through water.39 These studies highlight the importance of 
including the contribution of water molecules in rational ligand design. 
Several studies have shown the utilization of structural waters at binding sites in 
ligand optimization efforts – either promoting water mediated interaction or designing an 
analogue that displaces it. One such example that illustrates the importance of water 
molecules at active site and its exploitation in inhibitor design is that of HIV-1 protease. 
The unliganded crystal structure of HIV-1 protease40 shows the presence of catalytically 
important water Wat300, coordinated to an Asp residue in its active site. This water 
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molecule is consistently displaced when a ligand binds, disrupting the enzyme’s 
catalytic activity. Another water molecule in its active site, Wat301, that forms hydrogen 
bonds with backbone amides of the two symmetry related Ile residues, is detected in 
crystal structures of the protease in its free form and in complexes with different 
ligands.41 The conservation of this water molecule initially led to efforts directed at 
designing ligands that provide hydrogen bond acceptors to the protons of Wat301, 
resulting in potent inhibitors. However, ligands designed to displace this water proved to 
be even more tight binders, owing to the gain in entropy achieved by releasing that 
water into bulk solvent.42,43 In another study, a nitrile substitution in the quinalozine and 
benztriazine inhibitors of scytalone dehydrogenase with an aim to displace water 
molecule from the active site, again resulted in more potent inhibitors.44 Similarly, 
introduction of a nitrile group into quinazoline-based inhibitors of EGFR kinase led to 
more potent inhibitors, with the cyano-group interacting with the active site Thr in a 
similar manner to a water molecule.45 Such studies and many more, have indicated that 
water molecules can be viewed as an extension of or addition to protein structural 
features, and they should be treated explicitly to assist rational ligand design and also 
guide modeling techniques like ligand docking / protein-protein docking.  
 
 
1.4 Free Energy and Binding Affinity  
The previous sections shed light on the different molecular interactions prevalent 
in protein-ligand complexes – direct molecular interactions, as well as the influence of 
water molecules. Drug discovery efforts largely rely on the accurate assessment of all 
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different effects that might influence the binding of small-molecule ligands with the 
target protein. The quantitative knowledge of the forces that guide the binding process 
thus becomes very important. The binding affinity of two molecules to form a complex 
must be rationalized and understood in terms of Gibb’s Free Energy (Δ𝐺). 
A non-covalent, reversible association of protein (𝑃) and ligand (𝐿) to form a 
protein-ligand complex (𝑃′𝐿′ ) usually occurs in an aqueous solution, and can be 
represented by the following equation – 
 𝑷𝒂𝒒. +   𝑳𝒂𝒒.   ⇄ 𝑷′𝑳′𝒂𝒒. (2) 
 
 Under thermodynamic equilibrium conditions, the association constant 𝐾! (or the 
dissociation constant 𝐾!) is given by the following equation – 
 𝑲𝒂 =   𝑲𝒅!𝟏 =    𝑷′𝑳′𝑷 𝑳  (3) 
 
 The experimentally determined dissociation constant 𝐾!  (in case of enzyme 
inhibition, the inhibition constant 𝐾!) can be related to the standard Gibb’s free energy 
change of the dissociation (∆!𝐺°) of 𝑃!𝐿! as – 
 ∆𝒅𝑮° =   𝑹𝑻𝒍𝒏𝑲𝒅 (4) 
 
where 𝑅 is the gas constant and 𝑇 is the absolute temperature (𝑇 = 298 K). 
 The more negative the value of ∆𝐺°, the smaller the dissociation constant 𝐾!, and 
the stronger the binding. This relationship shows that the affinity of a molecule towards 
a target protein can be determined by calculating the associated changes in the 
thermodynamic parameters of the system – the changes in standard enthalpy and 
standard entropy upon complex formation. 
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 It is generally accepted that protein-ligand binding events are determined by not 
only electrostatic interactions like hydrogen bonds, salt bridges, dipole-dipole 
interactions, interactions with metal ions, but also contributions from 
solvation/desolvation processes and spatial complementarity in van der Waals 
interactions.46 The binding process is a complex phenomenon, and the enthalpy and 
entropy changes associated with direct interaction between protein and ligands are 
often not sufficient to describe the free energy change of the entire system. In the 
biological environment, both interacting partners are solvated before binding. The first 
event in the binding process is the desolvation of the ligand molecule and the protein-
binding site, which contributes to free energy changes. Next is the conformational 
change in the protein side chains and ligand molecule, which also results in a change of 
entropy. This is followed by the energy gain attained from the molecular interactions 
forming between the interacting partners. Finally, if solvent accessible, the protein-
ligand binding site is resolvated; with a favorable free energy if water molecules are set 
around polar/ionic groups and an unfavorable free energy if they are largely around 
hydrophobic groups. The total free energy change of the system (∆𝐺!"#$)  arises from 
contributions from each step of the binding process, and should be taken into account in 
calculations. The master equation can be written as – 
 ∆𝑮𝒃𝒊𝒏𝒅 =   ∆𝑮𝒔𝒐𝒍𝒗𝒆𝒏𝒕 +   ∆𝑮𝒄𝒐𝒏𝒇 +   ∆𝑮𝒊𝒏𝒕 +   ∆𝑮𝒎𝒐𝒕𝒊𝒐𝒏 (5) 
 
where, ∆𝐺!"#$%&'  is the hydration free energy, ∆𝐺!"#$  free energy contribution due to 
conformational changes in the protein and ligand, ∆𝐺!"# is the free energy change due 
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to specific interaction between protein and ligand, and ∆𝐺!"#$"%  is the free energy 
change due to “motion” in protein and ligand once they are proximal.47 
1.4.1 Experimental measurement of binding free energy  
Experimental determination of binding affinities can be achieved by indirect 
methods like binding assays. For enzyme reactions, the influence of ligand binding on 
enzyme kinetics results in a change in some physical property (like absorption, 
fluorescence, fluorescence polarization), which is subsequently measured. For receptor 
binding studies, a suitably labeled ligand is used. In both cases, the measured property 
is used to indirectly determine the binding constant and the standard free energy 
change (∆𝐺°). Recently, physicochemical techniques like Surface Plasmon Resonance 
spectroscopy,48 NMR spectroscopy,49 Mass spectroscopy,50 and also Atomic-Force 
microscopy51 have been used for indirect measurements of binding constants. A more 
direct measurement of binding affinities can be accomplished through microcalorimetric 
measurements, such as using Isothermal Titration Calorimetry (ITC). ITC is a highly 
versatile technique that allows determination of the complete thermodynamic profile 
(binding constant K, stoichiometry n, enthalpy change ΔH, entropy change ΔS) of a 
protein-ligand interaction from a single label-free experiment.52 
For medicinal chemists, the affinity of small-molecule ligand for a 
macromolecular protein is of utmost importance as it serves as a benchmark criterion to 
define its biological activity. Lead discovery and optimization process is aimed at 
attaining better binding affinities by improving the intermolecular interactions, thereby 
leading to more potent drug candidates. However, synthesizing every potential 
analogue of a prototype candidate molecule and its subsequent experimental binding 
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affinity determinations are impractical, as they demand substantial resources. A more 
rapid, cost-efficient, approach would be to computationally predict the binding affinities 
of these analogues, which in turn will aid in selection of lead compounds or drug 
candidates with more favorable chemical characteristics.  
1.4.2 Theoretical calculation of binding free energy  
Various theoretical approaches for prediction of binding affinities have been well 
documented in literature.15,46,53 Classical molecular mechanics forcefield-based scoring 
functions quantify protein-ligand interaction by focusing mostly on the steric and 
electrostatic forces involved. The solvation/desolvation effects and entropic 
contributions to binding events are often poorly described, and in some cases ignored.54 
Empirical scoring functions, on the other hand, are designed to approximate the binding 
affinities based on the individual interactions within a protein-ligand complex. The 
individual interaction terms accounting for favorable enthalpic contributions arising from 
electrostatic and hydrophobic contacts, as well as unfavorable entropic contributions 
arising from immobilization of rotatable bonds upon complex formation, may be 
implemented in the scoring function. The dependence of these methods on the quality 
of experimental data sets used to perform regression analysis and fitting, is a major 
reason for lack of accuracy in some approaches.54 A third category of scoring functions 
– knowledge-based scoring functions – are based on simple atomic interaction-pair 
potentials derived from the observed frequencies of atom-pairing within crystal 
structures of known protein-ligand complexes.55 Similar to empirical methods, a 
knowledge-based scoring function attempts to implicitly account for enthalpic and 
entropic contributions to binding. Despite the increasing number of scoring functions 
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being developed for accurate predictions of binding affinities, no general-purpose 
function is available. Most make various assumptions and simplifications for faster 
calculations, and do not completely describe every physical phenomenon involved in 
molecular recognition.54 Indeed, the binding phenomenon itself is complex, with many 
moving parts, and only partially understood. 
 
 
1.5 The HINT (Hydropathic INTeraction) Model56-58 
Kellogg and Abraham designed a novel empirical force field named HINT 
(Hydropathic INTeraction) for calculating intermolecular interactions and free energies, 
based on experimentally determined partition coefficients 𝐿𝑜𝑔  𝑃!/!.  
The octanol/water partition coefficient (𝐿𝑜𝑔  𝑃!/!) of a molecule A is the ratio of its 
equilibrium concentration in a mixture of two immiscible solvents – 
 𝑳𝒐𝒈  𝑷𝒐/𝒘 = 𝑳𝒐𝒈   𝑨 𝒐𝒄𝒕𝒂𝒏𝒐𝒍𝑨 𝒘𝒂𝒕𝒆𝒓  (6) 
 
1-octanol is a hydrophobic solvent that serves as a model environment to represent the 
biological phospholipid membrane. Thus, the distribution of a compound between water 
and 1-octanol provides accurate approximation of its partitioning between the cytosol 
and lipid membranes of living systems. The solvent partitioning phenomenon, much like 
the molecular recognition process, is governed by the same set of forces – the polar 
and electrostatic interactions guide the polar part of a molecule towards hydrophilic 
solvent (water) and the hydrophobic interactions guide the hydrophobic part of the 
molecule towards hydrophobic solvent (1-octanol). As a result, 𝐿𝑜𝑔  𝑃!/! values implicitly 
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include the effects of entropy and solvation, along with other non-covalent interactions 
like hydrogen bonding, Coulombic, acid-base, hydrophobic interactions, etc. The HINT 
model uses the 𝐿𝑜𝑔  𝑃!/! values for classification and quantitative scoring of molecular 
interactions, thereby incorporating both polar and hydrophobic complementarity, 
collectively referred to as hydropathy, between biomolecules. The quantitative solvent 
partitioning measurement (using experiments like the shake-flask method) can be 
viewed as free energy experiments and encode thermodynamic information, such that 
the standard free energy change of the solute transfer process (∆𝐺°) can be related to 
its equilibrium constant (𝐿𝑜𝑔  𝑃!/!) using the following equation – 
 𝑳𝒐𝒈  𝑷𝒐/𝒘 =   −  ∆𝑮° 𝟐.𝟑𝟎𝟑  𝑹𝑻 (6) 
 
where R is the gas constant and T is the absolute temperature. Thus: 
 𝑳𝒐𝒈  𝑷𝒐/𝒘 =   𝒌  ∆𝑮° (7) 
 
where 𝑘 = –0.733 kcal/mol at 298K. 
This relationship shows that HINT force field, which is based on 𝐿𝑜𝑔  𝑃!/!, can be used 
to estimate the free energy of a binding process, and thereby predict the binding 
affinities of ligands. 
 The HINT molecular interaction model calculates free energy scores for the 
hydropathic interactions within/between biomolecules by quantifying each atom-atom 
pair interaction using the following equation – 
 𝒃𝒊𝒋 =   𝒂𝒊  𝑺𝒊  𝒂𝒋  𝑺𝒋  𝑻𝒊𝒋  𝑹𝒊𝒋 +   𝒓𝒊𝒋 (8) 
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where 𝑏!"  is the hydropathic interaction score between atoms 𝑖  and 𝑗 . 𝑎  is the 
hydrophobic atom constant, 𝑆 is the solvent accessible surface area (calculated using a 
H2O probe), 𝑇!" is a logic function assuming +1 or –1 value depending on the character 
of the interacting polar atoms, and the distance dependent functions 𝑅!"   and 𝑟!"   are 
simple exponential function e-r and an implementation of the Lennard-Jones potential 
function, respectively. The total score of the system is then calculated by taking a 
double sum over every atom-atom pair – 
 𝑯𝑰𝑵𝑻𝒕𝒐𝒕𝒂𝒍 =   𝚺  𝚺  𝒃𝒊𝒋 (9) 
 
The HINT force field scores favorable interactions with 𝑏!" > 0 , and unfavorable 
interactions with 𝑏!" < 0 . The value of logic function 𝑇!"  depends on the type of 
interacting atoms. A favorable hydrophobic-hydrophobic interaction gets a 𝑇!" =   +1 
value; an unfavorable hydrophobic-polar interaction gets a 𝑇!" =   −1 value; for a polar-
polar interaction, 𝑇!" =   +1 if the interacting atoms are an acid and a base, whereas 𝑇!" =   −1 for an unfavorable acid-acid/base-base type interaction. Table 1.1 shows the 𝑇!" interaction matrix. 
The hydrophobic atom constant, 𝑎, is calculated by an adaptation of a partitioning 
algorithm CLOP of Hansch and Leo,59 which calculates the total solvation partition 
constant for a molecule by summation of fragment constants into a single value. HINT, 
on the other hand, uses a slightly different approach – it distributes and assigns 
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Table 1.1 – 𝑇!" interaction matrix57 
Atom Type 
[atom constant] 
H (apolar) 
[ a > 0 ] 
H (polar) 
[ a > 0 ] 
C (apolar) 
[ a > 0 ] 
Polar (N, O, etc) 
[ a < 0] 
H (apolar) 
[ a > 0 ] + 1 - 1 + 1 - 1 
H (polar) 
[ a > 0 ] - 1 - 1 - 1 + 1 
C (apolar) 
[ a > 0 ] + 1 - 1 + 1 - 1 
Polar (N, O, etc) 
[ a < 0] - 1 + 1 - 1 - 1 
Colors code: Green – favorable hydrophobic-hydrophobic; Red – unfavorable 
hydrophobic-polar; Blue – favorable acid-base or hydrogen bond; Yellow – unfavorable 
acid-acid; Orange – generally unfavorable base-base, but may depend on charge. 
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hydrophobic atom constants and factors to each atom in the molecule. HINT uses 
values from a functional group primitive dataset of small molecules and bio-
macromolecules, with re-parameterized force field atom types; modified factors for 
bond, branching, ring and chain factors; and polar proximity factors. The modifications 
represent real biophysical phenomena related to the molecular structure and properties. 
The hydrophobic atom constant for every atom of the molecule is calculated by 
modifying the factors based on the atom’s structural connectivity and proximity to other 
atoms. The 𝐿𝑜𝑔  𝑃  of the molecule can be considered as the sum of individual 
hydrophobic atom constants (𝑎!) – 
 𝑳𝒐𝒈  𝑷 =   𝚺  𝒂𝒊 (10) 
 
Most importantly, the hydrophobic atom constant is a thermodynamic parameter whose 
sign and magnitude reveals the potential type and strength of the interaction that the 
atom may engage in. 
 One of the most significant aspects of the HINT model is that it is empirical in 
nature and approximates all non-covalent interactions in the biological environment, 
including hydrogen bonding, electrostatic and hydrophobic interactions. Moreover, 
entropy and solvation/desolvation effects are also implicitly encoded in the 𝐿𝑜𝑔  𝑃 data. 
The hydrophobic atom constants (𝑎!) are parameters directly derived from the free 
energy of atom transfer between two solvents – which means that these solvents serve 
as model environments for hydrophobic and polar regions of biomolecules and the free 
energy of atom transfer between hydrophobic and polar regions of biomolecules is the 
same as that between 1-octanol and water. That is, the 𝑎! values of each atom indicate 
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how it will interact with other atoms in a biological micro-environment, much as how it 
interacts with solvent molecules/atoms. For example, for atoms 𝑖 and 𝑗, positive values 
of 𝑎! and 𝑎! imply that they are hydrophobic and the HINT algorithm would score the 𝑖/𝑗 
interaction favorably (𝑏!" > 0). If 𝑎! and 𝑎! are both negative, and one is a Lewis acid 
while the other is a Lewis base, the HINT algorithm would score the 𝑖/𝑗 interaction 
favorably also ( 𝑏!" > 0 ). However, if 𝑎!  is positive and 𝑎!  is negative, the 𝑖/𝑗 
hydrophobic-polar type interaction would be scored unfavorably (𝑏!" < 0). Table 1.2 
shows the matrix of atom-atom interaction types characterized and scored by the HINT 
algorithm. 
 
 The HINT force field and its free energy scoring form the basis for quantitative 
assessment of molecular interactions, which as we have discussed before, has a direct 
consequence in drug design. Within a homogeneous biological set (i.e., within families 
of different ligands binding to the same protein site), HINT scores can be easily 
correlated to the binding free energy associated with protein-ligand complex formation. 
Kellogg et al. have shown that total HINT interaction scores correlate with the ∆𝐺!"#$"#% 
(Figure 1.1) for a diverse set of 76 protein-ligand complexes at resolution better than 3.2 
Å, with a standard error of ± 2.33 kcal mol-1 using the equation –  
 ∆𝑮𝒃𝒊𝒏𝒅𝒊𝒏𝒈 =   −𝟎.𝟎𝟎𝟏𝟗  𝑯𝒕𝒐𝒕𝒂𝒍 − 𝟑.𝟗𝟐𝟕 (11) 
 
A better correlation was achieved within a subset of 56 complexes structurally 
determined at a resolution better than 2.5 Å (r = 0.85, SE = ± 1.8 kcal mol-1).60 
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Table 1.2 – Types of atom-atom interactions characterized and scored by HINT force 
fields57 
 
 Hydrophobic Polar – Lewis Acid (H-bond donor) 
Polar – Lewis Base 
(H-bond acceptor) 
Hydrophobic Hydrophobic interaction 
Hydrophobic – Polar 
(desolvation energy) 
Hydrophobic – Polar 
(desolvation energy) 
    
Polar – Lewis Acid 
(H-bond donor) 
Hydrophobic – Polar 
(desolvation energy) Coulombic repulsion 
Acid – Base 
(Hydrogen bond) 
    
Polar – Lewis Base 
(H-bond acceptor) 
Hydrophobic – Polar 
(desolvation energy) 
Acid – Base 
(Hydrogen bond) Coulombic repulsion 
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Figure 1.1 Correlation between calculated HINT scores and measured free energy of 
binding for 76 diverse protein-ligand complexes (crystallographic resolution better than 
3.2 Å). Reprint from ref 60. 
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 The capability of predicting the free energy of binding, especially since it has 
terms for hydrophobic interactions, in addition to the electrostatic, van der Waals and 
desolvation, makes HINT a suitable tool for scoring predicted binding modes of ligands 
in a docking experiment, in order to identify the best conformation. Several studies have 
successfully used HINT to distinguish active molecules from inactive ones.61-64  
 One of the earliest applications of HINT was incorporation of the HINT 
hydropathic fields into 3D-QSAR program CoMFA,65 which originally had just two fields, 
steric and electrostatic. The introduction of hydropathic field enables full description of 
binding events and aids in designing new molecules based on such QSAR studies, 
especially in cases where ligands and/or active sites are predominantly non-polar in 
nature. Several studies based on the HINT–CoMFA are reported in the literature.66-69 
An important consideration for reliable modeling results is the exact designation 
of protonation state of ionizable groups of both protein side chains and ligands, which 
can have significant influence on binding affinities. The hydropathic analysis can be 
performed using the HINT force field to assign the location of hydrogens on functional 
groups within the binding pocket, using an extension of the HINT model known as 
Computational Titration.70 Multiple potential ionization states for protein and ligand are 
enumerated and analyzed by the HINT model, with the best scoring complex 
representing the optimum state of binding and its corresponding protonation ensemble. 
As discussed before, interfacial water molecules mediate and stabilize the 
molecular recognition phenomenon – either directly via hydrogen bonding network or 
indirectly via solvation/desolvation processes. The contribution of bulk solvent towards 
the hydrophobic effect (the desolvation energy, entropic in nature) is implicitly encoded 
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within the 𝐿𝑜𝑔  𝑃!/! data. However, the solvent molecules forming bridging interactions 
between ligand and protein must be explicitly accounted for. The HINT force field can 
calculate the global interaction score for a water-mediated protein-ligand interaction 
(𝐻𝑆!"!#$) by incorporating the contribution made by water – 
 𝑯𝑺𝒕𝒐𝒕𝒂𝒍 =   𝑯𝑺𝒑𝒓𝒐𝒕!𝒍𝒊𝒈 +   𝑯𝑺𝒍𝒊𝒈!𝒘𝒂𝒕𝒆𝒓 +    𝑯𝑺𝒑𝒓𝒐𝒕!𝒘𝒂𝒕𝒆𝒓  (12) 
 
where, 𝐻𝑆!"#$!!"# is the interaction score between protein and ligand; 𝐻𝑆!"#!!"#$% is the 
interaction score between ligand atoms and water molecules; and 𝐻𝑆!"#$!!"#$% is the 
interaction score between protein atoms and water molecules (at the binding site), 
which can be ignored if those waters are preexisting, i.e., part of the protein. This global 
interaction score was shown to correlate with experimentally determined binding 
constants better than the scores when waters were ignored (SE = ± 0.98 kcal mol-1).71  
 The capabilities of HINT force field, and tools based on it, make it a highly 
versatile tool with numerous applications in drug designing. The HINT toolkit, a set of 
linkable subroutines that access HINT energy scoring functions and HINT 3D grid map 
objects, is made available to the scientific community and can be incorporated into 
programs for computer aided drug discovery.72 
 
 
1.6 Research Plan 
In addition to quantitatively scoring molecular interactions, the HINT force field 
can – (i) create hydropathic fields for ligands within a protein environment, (ii) rationally 
evaluate the correct ionization states of functional groups within a protein binding site, 
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(iii) incorporate energetic contribution of interfacial waters, and (iv) enhance 
crystallographic data by optimizing the protein residue interaction environment. The 
overall aim of this research work was to utilize the HINT force field and HINT-based 
computational tools in various aspects of molecular modeling. Our overarching goal is to 
apply this atomistic-level simulation technology to important biological proteins in order 
to gain structural insights into their mechanism of action that can be exploited for 
designing compounds intended to inhibit them. 
Sphingosine Kinase (SphK) is a key regulator of the sphingosine rheostat, which 
maintains optimum levels of a lipid metabolite sphingosine-1-phosphate (an anti-
apoptotic agent).73 Overexpression and/or upregulation of SphK have been associated 
with various aspects of cancer development.74-76 Biological characterization of a 
thiazolidine-2,4-dione (TZD) analogue identified it as an isoform-selective SphK2 
inhibitor.77 We asked ourselves if the key structural features of the ligand and the 
protein binding site, which makes it isoform selective, could be identified using the HINT 
force field. This is important to optimize the lead compound for future drug development. 
In Chapter 2, we will discuss the protein structure building process for the two human 
isoforms of SphK (SphK1 and SphK2). This was followed by molecular docking of the 
ligand to its putative binding site on the kinases. Using molecular docking and HINT free 
energy scoring to identify the probable native-like conformation of ligand within the 
binding pocket, we propose a binding mode for the TZD-analogue showing a preference 
for SphK2. 
 Human cytomegalovirus (HCMV) is a human pathogen responsible for diseases 
in immune-compromised and HIV patients, and severe birth defects when acquired 
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during pregnancy.78 The HCMV Alkaline Nuclease (AN) UL98, vital for viral replication, 
represents a novel target for development of antivirals.79 In the absence of a 
crystallographic structure, we wanted to see if molecular modeling techniques could be 
used to build a structural model to identify UL98’s catalytically important residues. In 
Chapter 3, we will discuss the homology-based structural modeling of UL98 AN. The 
computational model has been experimentally validated, and subsequently used to 
perform a structure-based virtual screening with an aim of identifying novel agents 
capable of inhibiting UL98. 
 Finally, in Chapter 4 we will discuss the utility of HINT based tools in designing a 
solvated protein-protein docking protocol. With increasing interest in targeting protein-
protein associations to interrupt biochemical pathways, and relatively few crystal 
structures of protein-protein complexes available, it becomes very important to have 
computational tools for accurate prediction of these biomacromolecular associations. 
Various HINT-based studies have shown the importance of interfacial waters in 
mediating and stabilizing protein-protein complexes.71,80-82 The majority of current 
docking algorithms include the effects of solvent by introducing desolvation energy 
terms in their scoring functions; however, they fail to account for the water molecules 
involved in bridging interactions. With HINT-based tools that can explicitly account for 
interfacial waters at our disposal, we wanted to check the influence of accounting for 
their energetic contributions on the outcome of docking predictions. Using these tools, 
we have designed a solvated protein-protein docking protocol that explicitly models the 
Relevant bridging interfacial waters, and demonstrate that more accurate results are 
obtained.
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CHAPTER 2 
THIAZOLIDINE-2,4-DIONE (TZD) ANALOGUE K145 – SELECTIVE SPHK2 INHIBITOR 
 
 
 
2.1 Introduction 
 
2.1.1 Sphingolipids – Structure and Function 
Sphingolipids and glycosphingolipids are complex lipids containing the sphingoid 
backbone, i.e., a long-chain aliphatic C18 – C20 backbone linked to a fatty acid via its 
acyl group, and attached to a charged head group such as ethanolamine, serine or 
choline through an O-linkage. Sphingosine and dihydrosphingosine, which are just long-
chain sphingoid bases are the simplest possible functional sphingolipids. Ceramide, a 
complex sphingolipid, has a fatty acid linked to the base by an amide bond. More 
complex sphingolipids are formed by addition of head groups to ceramide, such as 
sphingomyelins and cerebrosides that contain phosphocholine/phosphoethanolamine 
and glucose/galactose attached to the 1-hydroxy group of ceramide by an ester linkage 
and β-glycosidic linkage, respectively. Figure 2.1 shows the general structures of some 
sphingolipids. 
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Figure 2.1 – General structures of common sphingolipids 
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 Sphingolipids play very important structural and functional roles in the plasma 
membranes of eukaryotic cells.1 Over the last decade, significant studies have also 
shown their importance in non-structural roles. Sphingolipids have been demonstrated 
to be an important signaling mediator for vital cellular and physiological processes such 
as cell motility, invasion, proliferation, angiogenesis and apoptosis.2-6 Sphingolipids and 
their metabolites contribute to various cellular signaling pathways either by directly 
interacting with GPCRs or by acting as intracellular second messengers capable of 
interacting with a plethora of targets.7 Plasma membranes of many cell types contain 
lipid rafts, which are involved in various cellular processes like signal transduction, 
membrane trafficking, cytoskeletal organization, and, inside the nervous system, 
implicated in neuronal adhesion, axon guidance and synaptic transmission.8,9 These 
lipid rafts are enriched in sphingomyelin, ceramide and glycosphingolipids. 
Sphingolipids function as secondary messengers by interacting with a number of 
proteins and are capable of modifying the activity of various receptors, enzymes and ion 
channels, as well as mobilizing intracellular calcium.7 Figure 2.2 shows an overview of 
the roles of sphingolipids in cell biology. 
 The bioactive sphingolipids – sphingosine, sphingosine-1-phosphate and 
ceramide – are the central players of sphingolipid-mediated biology. Ceramide and 
sphingosine have been associated with growth arrest and apoptosis induced by tumor-
necrosis factor (TNF) α and Fas ligand.10,11 In contrast, sphingosine-1-phosphate (S1P) 
has been demonstrated to play pro-survival roles. S1P induces mitogenesis and acts as 
a secondary messenger in cellular proliferation induced by platelet-derived growth factor 
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Figure 2.2 – Scheme showing the participation of bioactive sphingolipids – ceramide, 
sphingosine and sphingosine-1-phosphate (S1P) in cell biology.  
Breakdown of various sphingomyelins by sphingomyelinases (SMases) generates 
ceramide. Ceramide can also be synthesized de novo by serine palmitoyl transferase 
(SPT) and ceramide synthase. Sphingosine and S1P are generated by ceramidases 
(CDases) and sphingosine kinases (SKs). These sphingosine metabolites interact with 
specific targets like phosphatases, kinases and GPCRs, which in turn mediate the 
effects of these lipids. Adapted from ref 11. 
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and serum.12-14 The intracellular levels of these metabolites and their regulatory effects 
on the members of MAPKs, rather than their absolute amounts, determine cell fate.10 
Regulation of the levels of these sphingolipids, a so-called “sphingolipid rheostat”, is 
complex and a number of enzymes have been demonstrated to be important (Figure 
2.3).6,11  
 
 
Figure 2.3 – The Sphingosine Rheostat: Cell fate determinant. 
 
 Studies have suggested the possible role of S1P signaling and the Sphingosine 
rheostat in carcinogenesis, with sphingolipid metabolism often disregulated.15 Exploiting 
the opposing effects of these interconvertible metabolites on cell proliferation for 
therapeutic benefit has emerged as an exciting strategy against cancer. 
 
2.1.2 Sphingosine Kinases and Cancer 
 A key regulator of the sphingosine rheostat is Sphingosine Kinase (SphK), the 
enzyme that phosphorylates sphingosine to sphingosine-1-phosphate (S1P), thereby 
producing the pro-growth, anti-apoptotic messenger. On the other hand, SphK 
decreases the levels of pro-apoptotic sphingosine, and in turn, ceramide. Various 
studies have shown that a cell is protected against ceramide-induced apoptosis with 
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increased levels of S1P, whereas depleted levels of S1P enhance ceramide-induced 
apoptosis.10,16-18 Human sphingosine kinase exists as two isoforms – Sphingosine 
kinase 1 (SphK1) and Sphingosine Kinase 2 (SphK2). Although SphK1 and SphK2 
share a high degree of homology, they differ significantly in size, tissue distribution and 
subcellular localization.19 SphK1 and SphK2 have five conserved domains (C1 – C5) 
sharing approximately 50% identity, with SphK2 having about 200 more amino acids 
than SphK1. SphK1 mainly resides in the cytosol while SphK2 is present in different 
intracellular compartments, including the nucleus, endoplasmic reticulum and 
mitochondria.20,21 
 Over the past few years, evidence has accumulated that suggest associations of 
sphingosine kinases with various aspects of cancer development and progression, such 
as proliferation, migration, invasion and angiogenesis.22 The very first observation that 
proposed the possibility of SphK1 as an oncogene was the transformation of SphK1-
transfected NIH3T3 fibroblasts to form fibrosarcoma cells, accompanied by increased 
S1P formation.23 SphK1 expression has been reported to be upregulated in many 
different solid tumor types including breast, lung, kidney, stomach, ovary, uterine and 
colon.24-27 Spiegel et al. showed that enforced expression of SphK1 increased S1P 
levels and blocked breast adenocarcinoma MCF7 cell death induced by anti-cancer 
drugs, sphingosine and TNF-α.28 In another study investigating the significance of 
SphK1 in gastric cancer progression, it was observed that SphK1 protein levels were 
upregulated in gastric cancer lesions compared to that in adjacent noncancerous 
tissues, and patients with higher SphK1 expression have shorter overall survival 
times.29 Much less is known about SphK2. Recently, however, it has been shown that 
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downregulation of SphK2 inhibits the proliferation and migration of tumor cells, such as 
glioblastoma and breast cancer cells.30,31 A recent RNA interference study showed that 
tumor cell proliferation and migration/invasion were suppressed more by SphK2-
selective ablation compared to SphK1 ablation.32 
 There is substantial evidence that S1P, an anti-apoptotic, mitogenic sphingolipid 
metabolite generated by the sphingosine kinases, is involved in cancer. A number of 
studies have implicated the signaling pathways of S1P in cancer. It regulates processes 
such as inflammation, neovascularization, cell growth and survival; all of which are 
important for tumor growth/proliferation and motility. For a detailed review, please refer 
to Pyne et al.33 Figure 2.4 summarizes the role of S1P in cancer. 
 As previously mentioned, cell fate is regulated by the sphingosine rheostat and 
sphingosine kinases play a major role in maintaining the balance in levels of involved 
sphingolipid metabolites. Strategies that shift the ceramide-sphingosine-S1P rheostat 
towards the pro-apoptotic/anti-mitogenic ceramide and that inhibit the activity of SphKs 
below the optimum level for cancer-cell survival are potential avenues for combating 
cancer. The presented evidence of involvement of SphKs in cancer makes them an 
ideal target for modulating the sphingolipid-mediated signaling for therapeutic effects. 
Although a number of potent and selective SphK1 inhibitors have been developed and 
reported,6,34-36 only a few SphK2 inhibitors with moderate potency (Figure 2.5), such as 
ABC294640,37 SG-12,38 R-FTY720-OMe39 and trans-12,40 have been reported.  
  
	   39 
 
 
 
 
 
 
 
 
Figure 2.4 – Summary of role of S1P in cancer.  
S1P interacts with a family of GPCRs and regulates processes involved in cancer cell 
motility and proliferation. Reprint from ref. 33 
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Figure 2.5  - Structures of known SphK2 selective inhibitors. 
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2.1.3 Thiazolidine-2,4-dione Analog K145 – Selective SphK2 Inhibitor41 
 
(Z)-3-(2-aminoethyl)-5-(3-(4-butoxyphenyl)propylidene)thiazolidine-2,4-dione 
 
K145 
Recently, Dr. Zhang and his research group initiated the development of 
thiazolidine-2,4-dione (TZD) analogs as dual-pathway inhibitors of the ERK and Akt 
signaling pathways.42,43 The TZD scaffold has emerged as a privileged template in drug 
discovery and design because of its frequent appearance in hits in various potential 
anticancer agents.44,45 The 3-(2-aminoethyl)-TZD moiety of these inhibitors may be able 
to mimic the amino-hydroxyl sphingoid base suggesting the possibility of them being 
sphingosine kinase inhibitors (Figure 2.6). Also, it has been shown that an aromatic ring 
with an alkyl chain is an important structural feature of SphK inhbitors.35 All these 
observations led to the hypothesis that K145, a TZD analog, could be a SphK inhibitor.41  
Following the synthesis of K145, biochemical assays as well as in vitro and in 
vivo studies were performed in the labs of Dr. Zhang, Dr. Spiegel and Dr. Grant (Virginia 
Commomwealth University) to determine its inhibitory activity towards SphKs and its 
nature of inhibition, and to examine its apoptotic effects on human leukaemia U937 cells 
and demonstrate its in vivo efficacy as a potential lead anticancer agent. 
Notably, K145 inhibited the activity of SphK2 in a dose-dependent manner with 
an IC50 of 4.40 ± 0.05 µM, while no inhibition of SphK1 at concentrations up to 10 µM 
was observed (Figure 2.7A). In contrast, DMS (10 µM) a non-selective SphK inhibitor, 
S
N
O
O
NH2O
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showed inhibition of both SphK1 and SphK2. This indicated that K145 is a selective 
SphK2 inhibitor. Lineweaver-Burk analysis revealed a Ki of 6.4 ± 0.7 µM for SphK2 and 
indicated that K145 is a substrate (sphingosine) competitive inhibitor (Figure 2.7B). 
Further screening against ceramide kinase, Akt kinase, ERK1/2, PI3K, PKA and other 
kinases also demonstrated the relatively high selectivity for SphK2.41 
Biological characterization using human leukemia U937 cells demonstrated that 
K145 accumulated in U937 cells and inhibited the phosphorylation of FTY720, and also 
inhibited the growth of U937 cells, mainly through apoptotic effects. Furthermore, K145 
was shown to significantly suppress the growth of U937 tumors in nude mice and 
inhibited growth of JC tumor cells in BALB/c mice without apparent toxicity.41  
 These results strongly indicate that K145 is a selective SphK2 inhibitor 
and encourage further optimization of K145 as a novel lead compound to develop more 
potent and selective SphK2 inhibitors. This would be of great value as a 
pharmacological tool to complement the ongoing molecular and genetic studies, and 
help unravel the roles of SphK2 in different pathological and physiological conditions. It 
would be useful to have new and adaptable chemical scaffolds available as selective 
SphK2 inhibitors that can provide valuable information regarding structural requirements 
for designing new SphK2 inhibitors. 
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Figure 2.6 – Overlay of K145 (carbon: green) with Sphingosine (carbon: cyan) showing 
chemical similarity between the heterocycle of K145 and the amino-hydroxyl sphingoid 
head of sphingosine. 
 
 
 
 
Figure 2.7 – Biochemical assays showing K145 as a selective, substrate-competitive 
SphK2 inhibitor.  
(A) SphK1 and SphK2 activities were measured with 10 µM sphingosine in the absence 
or presence of the indicated concentrations of K145 or 10 µM DMS. Data expressed as 
percentage SphK activity in the absence of inhibitor. (B) SphK2 activity was measured 
with increasing concentrations of sphingosine and indicated concentrations of K145. 
Lineweaver-Burk analysis revealed a Vmax of 10820 ± 210 pmol/min per mg of protein, 
and a Ki of 6.4 ± 0.7 µM for SphK2. 
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2.1.4 Sphingosine Kinase C4 domain – A putative Sphingosine-binding domain 
 As mentioned before, both sphingosine kinase isoforms have five conserved 
domains C1 – C5, sharing about 50% identity (Figure 2.8). The domains, C1 – C3 and 
C5, share homology with other kinases like diacylglycerol kinase (DGK) and ceramide 
kinase (CerK), with the C2 domain containing the ATP-binding consensus sequence 
SGDGX17-21K.46,47 
 The C4 domain is highly conserved only in SphKs making it the only domain that 
might be specific for sphingosine binding. Yokota et al. constructed various mutants of 
mouse SphK1, within the C4 domain, in order to identify the residues important for 
sphingosine recognition. The negatively charged Asp175, Asp177, Glu179 and Glu181 
residues, in the C4 domain of mSphK1, were mutated to Asn and Gln. Also, double 
mutants mSphK1aD175N/D177N and mSphK1aD177N/E179Q were prepared. Each mutant was 
analyzed for SphK activity using D-erythro-sphingosine and ATP as substrates (Figure 
2.9). The results demonstrated that the highly conserved Asp177 is involved in 
sphingosine recognition.48 
 In order to identify the putative Asp residue involved in sphingosine-recognition in 
human SphKs, we performed a multiple sequence alignment between mouse SphK1a 
and human SphK1 and SphK2. Asp178 in hSphK1 and Asp344 in hSphK2 were 
identified as the residues corresponding to the Asp177 of mouse SphK1 in the C4 
domain (Figure 2.10). 
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Figure 2.8 – Schematic representation of human sphingosine kinase isoforms 
 
 
 
 
Figure 2.9 – Relative sphingosine kinase activities of mouse SphK1a mutants. 
(A) Schematic representation of mSphK1 showing the C4 domain and the residues that 
were mutated. (B) Relative SphK activities of mSphK1a mutants. The mutants were 
analyzed for SphK activity using D-erythro-sphingosine and ATP as substrates.48 
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Figure 2.10 – Sequence alignment of the C4 domain of sphingosine kinases.  
Asp178 (hSphK1) and Asp344 (hSphK2) were identified as the corresponding residues 
important for sphingosine-recognition. Sequence alignment was performed using 
Clustal X v2.0,49 image obtained using Jalview,50,51 sequences are colored using the 
default Clustal X color scheme (Appendix A.1). 
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2.1.5 Specific Aim 
 To further understand the SphK2 selectivity of K145, we conducted molecular 
modeling studies to identify the structural features of K145 that interact with the key 
residues of SphK2. Since the biochemical assays showed that K145 is a substrate 
(Sphingosine) competitive inhibitor of SphK2 (Section 2.1.3), we performed our studies 
on the C4 domain of both isoforms. In this chapter, we report the results of protein 
structure building followed by the docking studies of various reported Sphingosine 
kinase inhibitors. Finally, a binding mode for K145 within the putative sphingosine-
binding domain of SphK1 and SphK2 has been proposed. 
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2.2 Methods 
 
2.2.1 Structural Modeling of SphK1 and SphK2 
2.2.1.1 Template Identification and Alignment 
 Human SphK1 (Accession: Q9NYA1) and SphK2 (Accession: NP_001191088) 
sequences were obtained from the NCBI database (www.ncbi.nih.gov/protein/). A 
Position Specific Iterated BLAST52,53 search against the database of Protein Data Bank 
proteins was performed to identify a template structure. Diacylgycerol kinase from 
Bacillus anthracis str. Sterne (PDB ID: 3T5P) was identified as the closest match to both 
isoforms of SphK. Sequence alignments of each SphK1 and SphK2 with 3T5P were 
performed using Clustal X v2.0.49 Unaligned regions in both the proteins were deleted.  
2.2.1.2 Homology Modeling and Refinement 
A total of 100 homology models for each isoform were generated based on these 
alignments, using the automodel class of MODELLER 9v10.54 A DOPE (Discrete 
Optimized Protein Energy) Score55 and a GA341 Score56 was calculated for each model 
using MODELLER. The top 5 models for each kinase with lowest DOPE scores and 
molpdf scores (a MODELLER object function score) and with GA341 scores closest to 1 
were chosen for further refinement. The side chains for each model were optimized 
using SCWRL57 (dunbrack.fcc.edu/scwrl4/). Hydrogens were added to these top models 
using SYBYL v8.1 (TRIPOS Inc.) and subsequently subjected to Powell minimization for 
10000 iterations in Tripos force field with a 0.005 kcal/mol-Å termination gradient. The 
quality of minimized models was evaluated using MolProbity,58 which performs an all-
atom contact analysis to give a ‘clashscore’ that is indicative of the number of serious 
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clashes (>0.4 Å) per 1000 atoms. Poor side-chain rotamers and unreasonable bond 
lengths and angles were checked. Ramachandran plots were also generated using 
MolProbity to check the backbone-geometry of the models. Atom clashes and bad bond 
lengths and angles were optimized with further minimization. Sphingosine, the natural 
substrate for both kinases, was docked into the C4 domain (putative Sph binding 
domain, L163 – F197 for SphK1 and C329 – V363 for SphK2) of each model, using 
GOLD v5.1.59 The docked poses were scored using HINT.60 The “best” model of both 
SphK1 and SphK2 was then chosen based on its overall stability and its ability to 
accommodate Sphingosine in its C4 domain. 
 
2.2.2 Inhibitor Docking 
 The optimized models of both SphK1 and SphK2 were used for the docking 
studies. The structures of inhibitors were sketched using SYBYL v8.1, and subjected to 
minimization to get a low energy structure. The docking simulations were performed 
using GOLD v5.1. The binding site was defined to encompass all atoms within 20 Å of 
CA of Asp178 of SphK1 (Asp344 of SphK2). Fifty solutions for each inhibitor molecule 
were generated with a protein hydrogen-bond constraint that the carboxylate of Asp178 
of SphK1 (Asp344 of SphK2) forms a hydrogen bond with ligand, since the Asp is 
important for recognition of sphingosine (Section 2.1.4). The docked poses were scored 
using HINT. The poses with the best HINT scores were complexed with the protein and 
the protein-ligand complex was subjected to minimization (2500 iterations, termination 
gradient of 0.005 kcal/mol-Å), to remove steric clashes and get an induced-fit model. 
The binding modes of the ligands after minimization were re-scored using HINT. 
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2.3 Results and Discussion 
 
2.3.1 Structural Modeling of SphK1 and SphK2 
 Since no crystal structure is currently available for either SphK1 or SphK2, we 
generated their structural models using MODELLER, a comparative protein structure-
modeling program. First, a PSI-BLAST search was performed against the database of 
PDB proteins that identified a structure of Diacylglycerol kinase from Bascillus anthracis 
str. Sterne (PDB ID: 3t5p) as the template (Figure 2.11). The template structure shares 
~25% sequence identity and ~46% homology in the aligned regions to both SphK1 and 
SphK2. The primary amino acid sequences were aligned using Clustal X v2.0, the 
results of which are shown in Figure 2.12 and Figure 2.13. 
 Based on the sequence alignment, structural models of both isoforms of SphKs 
were generated using MODELLER. The program sets up spatial restraints on Cα-Cα 
distances, main chain N-O distances and main chain and side chain dihedral angles 
obtained from the template crystal structure,54 which is followed by modeling all non-
hydrogen atoms by violating these restraints as little as possible. The natural substrate 
for SphKs, sphingosine, was docked into the C4 domain of top 5 models of each kinase 
(based on lowest energy scores, refer Section 2.2.1.2) using GOLD (Genetic 
Optimization for Ligand Docking). GOLD performs automated ligand docking, using 
genetic algorithm to explore full ligand flexibility within the neighborhood of protein 
binding site.59 The generated binding poses are ranked by a simple scoring function that 
comprises of a hydrogen bonding term, a pairwise dispersion potential and a term for  
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Figure 2.11 – Overall fold of the template structure – Diacylglycerol kinase from 
Bascillus anthracis str. Sterne (PDB ID: 3t5p).  
Image prepared using PyMOL.61 
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Figure 2.12 – Sequence alignment of SphK1 with the template 3T5P (Diacylglycerol Kinase from Bacillus anthracis str. 
Sterne).  
Alignment performed using Clustal X v2.0. The alignment is colored based on the Clustal X color scheme (Appendix A.1). 
Image prepared using Jalview. 
 
 
	   53 
 
Figure 2.13 – Sequence alignment of SphK2 with the template 3T5P (Diacylglycerol Kinase from Bacillus anthracis str. 
Sterne).  
Alignment performed using Clustal X v2.0. The alignment is colored based on the Clustal X color scheme (Appendix A.1). 
Image prepared using Jalview.  
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internal energy of the ligand conformation.59 For our study, all the docked poses were 
scored using the HINT force field, as it accounts for all the hydropathic forces involved 
in the protein–ligand binding event. The “best” model of both SphK1 and SphK2 was 
then chosen based on its overall stability and its ability to accommodate Sphingosine in 
its C4 domain. Model044 was the best model for SphK1, with a clashscore of 3.2 (97th 
percentile) and with 96.8% residues in allowed regions on Ramachandran plots. 
Model055 was the best model for SphK2, with a clashscore of 2.03 (99th percentile) and 
with 98.5% residues in allowed regions on Ramachandran plots. Figure 2.14 shows the 
sphingosine-binding site of both SphK1 and SphK2. 
 
2.3.2 Model Validation by Inhibitor Docking 
The final optimized models for both proteins were further validated by docking a 
panel of inhibitors including the reported SphK2 selective compounds shown in Figure 
2.5, a SphK1 selective inhibitor, SK1-I,35 and FTY720, a compound known to bind to 
both SphKs.62,63 Docking and scoring studies were performed as described in Section 
2.2.2. As shown in Table 2.1, the HINT score results indicate that both FTY720 and its 
o-methoxy derivative (R)-FTY720-OMe bind to SphK2 preferably, over SphK1. SK1-I 
binds more favorably to SphK1, consistent with the reported biological results.35 We 
also docked SG-12, ABC294640 and trans-12b (Figure 2.5); the relative ordering of 
HINT scores (HTOTAL) are more or less in concordance with the reported 
binding/inhibitory observations (Table 2.1).37-40 While specific HINT score values 
generally should be calibrated for the specific biomacromolecular-ligand system, 
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Figure 2.14 – Structural models of SphK1 (A) and SphK2 (B).  
Both kinases are shown in cartoon representation, with their C4 domains in different 
color. The docked sphingosine molecule is shown as sticks. Image prepared using 
PYMOL. 
 
  
	   56 
previous studies consistently indicate that Δ(HINT score)/ ΔΔGbinding ~ –515, i.e. HINT 
score differences of around 515 correspond to 1 kcal/mol differences in binding 
energies.64,65 
Despite low overall homology to the template, there is considerable sequence 
and structural similarity at the sphingosine-binding domain (C4 domain), and we believe 
that these models will provide valuable structural information.  
 
 
 
 
Table 2.1 – HINT Scores for docked molecules (previously reported inhibitors) into the 
C4 domain of SphK1 and SphK2 
 
Ligand 
HINT Scoresa 
SphK1 SphK2 
FTY720 2347 2751 
(R)-FTY720-OMe 138 1878 
SG-12 1626 1876 
ABC294640 -73 153 
Trans-12b -935 218 
SK1-I 2080 679 
aPrevious studies have shown that ~515 score units correspond to ΔΔG = -1.0 kcal/mol.  
In the absence of a reference point from a calibration for this specific biomolecular 
system, the HINT score difference between ligands and/or between SphK1 and SphK2 
are more meaningful than their specific values. 
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2.3.3 Proposed Binding Mode for K145 
We then docked K145 to the two kinase models. The docking results revealed 
that K145 binds preferentially to SphK2 (Table 2.2), as it shows more favorable 
interactions in the sphingosine-binding pocket of SphK2 than that of SphK1. 
Specifically, as shown in Figure 2.15, our model indicates that the terminal –NH2 of 
K145 forms strong salt-bridge interactions with the carboxylate group of Asp344 (the 
putative sphingosine recognizing residue). Other favorable hydrogen bonding 
interactions are also formed between the guanidino-group of Arg351 and Gln346 with 
the carbonyl oxygens of the TZD heterocycle. The TZD ring of K145 shows favorable π-
stacking interactions with Phe350 and the 4-butoxy-phenyl ring of K145 fits into a 
hydrophobic pocket formed by the sidechains of Ala336, Val340, Val343, Arg617 and 
Val619. K145 shows a very similar binding mode within the C4 domian of SphK1. The 
terminal –NH2 of K145 forms salt-bridge interaction with Asp178 and the carbonyl 
oxygen at 2-position of TZD rings forms hydrogen-bonding interaction with Arg185. The 
TZD ring π-stacks with the aromatic ring of Tyr184 and the hydrophobic interactions of 
the tail with the surrounding hydrophobic residues are more or less conserved. In 
contrast to its binding mode in SphK2, the carbonyl oxygen at 4-position of the TZD ring 
showed an unfavorable base/base interaction with the carboxylate group of Glu180 (that 
corresponds to Gln346 of SphK2). Judging from the sequence similarity in the 
sphingosine-binding domains of both isoforms, the GlnèGlu change in SphK1 is the 
only significant difference in this region and might be the reason for K145 showing 
selectivity towards SphK2. 
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Table 2.2 – HINT Scores for K145 docked into the C4 domain of SphK1 and SphK2 
Ligand HINT Score SphK1 SphK2 
K145 1506 3011 
 
 
 
 
Figure 2.15 – Binding mode of K145 in SphK1 (A) and SphK2 (B).  
K145 is shown as sticks with carbon in green, while the interacting residues of both 
kinases are shown as sticks with carbon in cyan. For simplicity, hydrogens are only 
shown on residues forming hydrogen-bonding interactions with K145. Image prepared 
using PyMOL. 
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2.4 Conclusion 
Dr. Zhang and his group identified a thiazolidine-2,4-dione analog, K145, as a 
selective SphK2 inhibitor. Biochemical assays using recombinant SphK1 and SphK2 
established that K145 selectively inhibited SphK2 and not SphK1.41 In absence of any 
crystallographic data available for either isoform, we performed in-silico studies to gain 
structural insights into protein-ligand interaction. We successfully generated structural 
models of both sphingosine kinase isoforms, SphK1 and SphK2, using a known 
structure of diacylglycerol kinase from Bacillus anthracis str. Sterne as the template 
structure. K145 was then docked into the C4 domain of each model, and the protein-
ligand intermolecular interactions were elucidated using HINT scoring. 
Although these are tentative models built from a kinase of bacterial origin, their 
sphingosine-binding domains are more conserved than other regions, and the models 
are more than adequate as hypothesis generators for compound design. Nonetheless, 
our docking results do support the experimental assertion that K145 is a selective 
SphK2 inhibitor.  
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CHAPTER 3 
HOMOLOGY MODELING OF HUMAN CYTOMEGALOVIRUS ALKALINE NUCLEASE 
UL98 AND IDENTIFICATION OF POTENTIAL LEADS BY VIRTUAL SCREENING 
 
 
 
3.1 Introduction 
3.1.1 Human Cytomegalovirus (HCMV) – A human pathogen 
 Cytomegaloviruses, one of the major lineages in the Herpesviridae family, are 
present in a wide range of mammalian species. Since they have a higher tendency to 
infect the salivary gland, they are also termed as “salivary gland viruses”. Out of the 
eight human pathogens belonging to Herpesviridae family, human cytomegalovirus 
(CMV), also known as human herpes virus 5 (HHV-5), is the most extensively 
characterized member. It is a prototypic member of this subfamily with a large double-
stranded DNA genome of about 235 kbp in size, that consists of unique long and short 
segments, each surrounded by inverted repeats.1 
 HCMV infection is existent in most populations around the world, with overall 
HCMV seroprevalence ranging from 20%–100% in different countries. Higher 
seroprevalence, nearly up to 100%, has been observed in individuals from resource-
constrained countries; in contrast, adults from well-developed countries from Northern 
Europe and North America are associated with lower rates of 
	   66 
CMV infection.2 The overall age-adjusted CMV seroprevalence in the United States is 
~50%.3 
 Infectious cytomegalovirus can be found in various body fluids like tears, saliva, 
blood, urine and semen. CMV is spread easily with extended and repeated exposure to 
virus in infants/young children attending day-care facilities, hospitalized patients and 
hospital staff.4 Prolonged virus shedding from infected individuals seems to be a 
common source of CMV acquisition in the community. CMV transmission easily occurs 
by person-to-person contact or contact with contaminated surfaces. Infants, toddlers 
and young children are an important reservoir of the virus. The virus is efficiently 
transmitted among children attending the same child-care centers by constant physical 
contact, hand-to-mouth contact or by limited personal hygiene practices. A susceptible 
seronegative mother or a pregnant woman visiting the group care facilities is at a very 
high risk of infection, which in turn leads to congenital CMV infection of the fetus4. 
Lactating mothers act as a source of CMV to newborn babies due to ingestion of 
infected breast milk.5  Infected children readily transmit the virus to adults. The shedding 
of CMV virus via the genitourinary tract leads to its transmission among adults during 
sexual activity.6 Sources of CMV in hospitalized patients include blood product 
transfusions and transplanted organs from seropositive sources. Health-care workers 
are also at a risk of acquiring infection since they are in such environments for 
prolonged periods of time.  
CMV infections acquired in healthy people are usually mild and asymptomatic, 
and typically go unnoticed. On the other hand, CMV infections can have severe clinical 
and pathological manifestations leading to life threatening conditions in 
	   67 
immunocompromised patients, especially transplant recipients and HIV-positive 
patients.7 CMV pneumonitis is a major cause of morbidity and mortality in severely 
immunocompromised patients following solid organ transplantation or hematopoietic 
stem cell transplantation, even with treatment.8 In HIV-infected patients, a CMV 
infection causes serious ocular complications like retinitis, gastric complications leading 
to hemorrhage/perforations, and in some cases neurological damage causing paralysis 
or fatal encephalitis.9,10 Congenital and neonatal CMV infections are more serious and 
in many cases are life-threatening. In newborns congenital CMV infections are the 
leading cause of sensorineural hearing loss (SNHL), which may be present at birth or 
develop later in childhood.11,12 CMV infections acquired during pregnancy have been 
reported to cause learning disabilities and mental retardation.13 More recently, reports of 
CMV infections in immunocompetent patients with prolonged and relapsing illnesses 
involving fever, sweats, and in some cases abnormal liver functions, have been well 
documented.14,15 
 
3.1.2 Antiviral Therapy for CMV Infection 
 Over the past few years, major advances have been made in the treatment and 
prevention of CMV infections by the development of antiviral agents. Currently available 
licensed antivirals for CMV (Figure 3.1) include ganciclovir (Cytovene®), its valine ester 
prodrug valganciclovir (Valcyte®), foscarnet (Foscavir®), cidofovir (Vistide®), and 
Cytomegalovirus Immune Globulin (CytoGam®) (summarized in Table 3.1). 
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Figure 3.1 – Antivirals for cytomegalovirus infections 
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Table 3.1 – Summary of currently licensed antivirals for CMV infections (adapted from ref 1,11). 
 
Available Drug Dose Major Indications Associated Toxicities 
 
Ganciclovir 
    Cytovene® 
 
10–12 mg/kg/day IV 
 
Prophylaxis; 
Congenital and perinatal CMV infection; 
CMV retinitis; 
End-organ disease in 
immunosuppressed patients 
 
Hematotoxicity (mainly neutropenia, 
thrombocytopenia); 
Carcinogenic; 
Teratogenic 
 
Valganciclovir 
    Valcyte® 
 
– Prophylaxis; CMV retinitis 
Identical to its active metabolite – 
ganciclovir 
 
Foscarnet 
    Foscavir® 
 
90 mg/kg q 12h IV 
 
Prophylaxis; CMV retinitis; 
End-organ disease in 
immunosuppressed patients with 
ganciclovir-resistant infections 
 
Nephrotoxicity; 
Electrolyte imbalances; 
Teratogenic 
 
Cidofovir 
    Vistide® 
 
5 mg/kg q weekly 
 
End-organ disease in 
immunosuppressed patients with 
ganciclovir-resistant infections 
 
Nephrotoxicity; 
Ocular toxicity; 
Carcinogenic; 
Teratogenic 
 
Cytomegalovirus 
Immune Globulin 
    Cytogam® 
 
100–150 mg/kg, 
IV post-transplant 
Prophylaxis; 
Adjunctive treatment for CMV pneumonitis 
in immunocompromised patients 
Minimal toxicity 
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Ganciclovir (and its prodrug – vanciclovir) is a guanosine analog, which upon 
phosphorylation by the CMV UL97 kinase, acts as a chain terminator during viral DNA 
replication. Ganciclovir therapy is the treatment of choice for CMV related retinitis and 
pneumonitis in transplant patients.16-18 Foscarnet is a structural analog of 
pyrophosphate and inhibits the CMV DNA polymerase by binding at its pyrophosphate-
binding site and halts DNA chain elongation. DNA modifying enzymes in CMV produces 
pyrophosphate as one of the products, thus making Foscarnet a product inhibitor; and 
so unlike ganciclovir, it does not compete with natural nucleotides. It does not require 
activation by the phosphorylative enzymes of either the host or the virus. Foscarnet is 
an effective second-line treatment for CMV infections in HIV-patients and in cases 
which develop ganciclovir resistance.19 Cidofovir, like foscarnet, is a second-line therapy 
antiviral. It is an acyclic deoxycytidine monophosphate analog, which upon conversion 
to diphosphoryl metabolite by cellular enzymes inhibits the CMV DNA polymerase.20 
Cytomegalovirus Immune Globulin is an intravenous immunoglobulin preparation that is 
indicated for prophylaxis against CMV infections in transplant recipients. It is prescribed 
either alone, or in combination with any of the above-mentioned antiviral agents.11  
 All of the above drugs share a similar mechanism of action, i.e., inhibition of viral 
DNA polymerase and interfering with its DNA synthesis process. There are also 
significant toxicities associated with each of these drugs. In immunocompromised 
patients, ganciclovir is associated with bone marrow suppression, mainly 
granulocytopenia and thrombocytopenia. Ganciclovir, when used for a prolonged period 
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of time, is considered a potential human carcinogen, teratogen, and mutagen.21 The 
most important clinical problem that may emerge during foscarnet/cidofovir therapy is 
nephrotoxicity.22,23 Although suited for prophylaxis and treatment of CMV related 
infections in adults, evidence of teratogenicity in lab animals makes these drugs not 
ideal for treatment in pregnant women.24 Also, there is limited evidence for using these 
antivirals to treat congenital and perinatal HCMV infections.25 Patients receiving 
prolonged therapy are at the risk of developing resistance to these antivirals.26 A 
ganciclovir resistance study, on a group of AIDS patients suffering from CMV retinitis by 
Jabs D. A., et al., showed that about 11% of the patients developed resistant-strain 
virus within 6 months of treatment, and about 28% by 9 months.27 Being structurally so 
similar, it would be expected that a virus resistant to one compound would exhibit cross-
resistance to others. 
 Although these antiviral drugs have been useful in treating a range of CMV-
related infections, the toxicities and chance of developing resistance associated with 
them emphasize the need for developing less toxic novel antivirals, especially those that 
target alternate processes essential for viral survival. Safer, nonteratogenic antivirals 
could be used during pregnancy to treat fetal infections or in neonates to prevent CMV 
related mental retardation and SNHL.   
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3.1.3 HCMV Alkaline Nuclease UL98 – A novel target  
 The general idea behind developing antivirals against CMV is to identify and 
disable viral proteins that are important for its development. Novel compounds targeting 
different processes are desirable because of their potential to be used in combination 
therapy and to avoid resistant-strain viral development. Alkaline nucleases, encoded in 
all herpes viruses, represent one such target.  
   The herpesvirus alkaline nucleases are DNA-modifying enzymes that possess 
both 5’ – 3’ exonucleolytic activity and a slightly moderate endonucleolytic activity.28 
They have a high in vitro pH optimum and hence are termed “alkaline”. These enzymes 
can process both single-stranded and double-stranded DNA substrates, with a notable 
preference for supercoiled substrates. Different members of the Herpesviridae family – 
viz. Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Kaposi’s Sarcoma 
associated herpesvirus (KSHV) and Epstein-Barr Virus (EBV), encode the alkaline 
exonuclease. The majority of data on the biological role of these enzymes at different 
stages of viral development comes from studies on Herpes Simplex Virus type I (HSV-
1) Alkaline Nuclease – UL12, which is the first described, expressed and mapped 
herpesvirus alkaline nuclease.29 Although the exact function of alkaline nucleases in 
viral survival is unknown, studies have shown that HSV-1 AN is required for efficient 
processing of viral DNA replication intermediates, suggesting its role in maturation and 
packaging of viral DNA into capsids.30 Additional reports have indicated the importance 
of HSV-1 AN in the efficient egress of capsids from the nucleus.31  
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 Different genes involved in viral DNA replication, cleavage and packaging, are 
highly conserved among HSV-1 and CMV32; even though the HSV-1 genome is 
significantly smaller in size (~150 kb compared to ~235 kb of CMV). Predictions based 
on gene arrangement and amino acid sequence homology have indicated the HCMV 
UL98 gene to be the counterpart of HSV-1 UL12 gene. Trans-complementation 
experiments have demonstrated functional conservation of proteins encoded by the 
homologous genes of HSV1 and CMV.33 The UL98 protein encoded by the CMV UL98 
gene is indeed the conserved enzyme homolog of α- and γ- herpesvirus alkaline 
nucleases.34  
In vitro, HCMV UL98 AN shows both 5’ – 3’ exonuclease (exo) and 
endonuclease (endo) activities that are optimal at alkaline pH, similar to other ANs. It 
also can hydrolyze dsDNA and ssDNA substrates and requires a divalent cation for 
activity, with preference for magnesium ion.34 The role of UL98 alkaline kinase in CMV 
infection is extremely important, suggested by the fact that its synthesis starts at early 
stages of infection, with significant increase in its levels after the onset of viral DNA 
replication.35 In more recent studies, the global functional analysis of HCMV genome 
has identified the UL98 gene, which encodes the UL98 AN, as essential for viral 
growth.36,37 The fact that HCMV UL98 gene complemented an HSV-1 UL12 deletion 
mutant functionally can be used to assume a similar role of UL98 alkaline nuclease in 
CMV DNA modification, capsid stability and egress.33 Although the alkaline nuclease is 
	   74 
not required for viral DNA synthesis,38 there is enough evidence to emphasize the 
importance of UL98 AN in the different stages of CMV viral development.  
The plausible impact of UL98 AN on CMV viral growth, and the presence of an 
alkaline nuclease homologue in every herpesvirus, makes it a unique antiviral target for 
CMV infections. Unlike traditional approaches that target viral DNA synthesis by 
inhibiting DNA polymerase, this approach targets the late events in viral replication like 
viral DNA packing, capsid stability or egress. This would be beneficial to treat resistant 
infections and also prevent their occurrence with combination therapy. Also, identifying 
novel inhibitors of UL98 AN may help to overcome the modest antiviral activity of 
currently approved drugs and their dose-related toxicities, and result in a highly 
efficacious antiviral therapy, intended to be used in patients of all ages and conditions 
(infants, adults, pregnant women, transplant recipients, AIDS patients). 
 
3.1.4 Alkaline Nucleases  – Structural insights 
  A phylogenetic analysis, by Rychlewski, L., et. al., has classified the herpesvirus 
alkaline nucleases within the PD-(D/E)XK superfamily of DNases39. This family includes 
structurally well-characterized, functionally diverse members like restriction 
endonucleases40 (EcoRI and EcoRV), DNA-nicking enzymes (Vsr41 and MutH42), and 
bacteriophage λ exonuclease43 (λ-exo). Although these enzymes share little overall 
sequence similarity, they have a common core fold and a conserved, well-defined 
PDX10-30(D/E)XK motif that is involved in metal-binding and catalysis. The central core 
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region is formed of four-stranded, mixed β-sheets flanked by two α-helices on either 
side, with αβββαβ topology (Figure 3.2). The catalytic sites of these enzymes contain a 
conserved aspartic acid (D), an aspartic or glutamic acid (D/E) and a lysine (K).44 To 
date, crystal structures of two herpesvirus alkaline nucleases have been solved – the 
Kaposi’s sarcoma-associated herpesvirus Shut-off and Exonuclease45 (KSHV-SOX) and 
its Epstein-Barr virus (EBV) homolog BGLF5.46 They confirm the structural similarity of 
herpesvirus ANs to the PD-(D/E)XK superfamily, sharing a comparable central core fold 
and active-site formation. 
 Very little is known about the structure of CMV UL98 alkaline nuclease, apart 
from the fact that it too is a herpesvirus alkaline nuclease, and therefore should be 
structurally similar to proteins of PD-(D/E)XK superfamily. The knowledge of the three-
dimensional structure of UL98 AN is required for better understanding of its functional 
mechanism and to elucidate its exact role in virus growth and development. The recent 
computational advances in homology protein structure modeling have enabled reliable 
prediction of unknown protein structure based on a homologous protein of known 
structure. The model can then be potentially used for structure-based design of a novel 
class of antiviral drugs. 
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Figure 3.2 – The conserved PD-(D/E)XK core fold with active site formation (Reprint 
from ref 44). 
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3.1.5 Specific Aims 
 In the current work, we aim at identifying novel antiviral agents that target CMV 
UL98 AN using traditional computational approaches like homology modeling and 3D 
virtual screening on the protein model. The working hypothesis that underlies this 
project is that the nuclease activity of UL98 is critical for HCMV viral development and 
targeting it may lead to a novel, efficacious antiviral therapy for CMV infections, with 
reduced toxicities. The work has been divided into two specific aims:  
1) Structural modeling of CMV UL98 AN, and 
2) Virtual screening on the active-site of UL98 AN model 
The first part of this work involved homology-based structural modeling of UL98 
AN in order to identify the active-site residues. The active-site residues were validated 
using mutagenesis, in the lab of Dr. Michael McVoy, Professor of Pediatrics, Molecular 
Biology and Genetics, School of Medicine, VCU. Mutant viral construction was also 
performed to show the importance of UL98 in CMV replication. The computational work 
has been described in detail in the following sections, and the findings have been 
recently published (Kuchta et al).47 
 The second part of the work involved structure-based drug discovery on the 
UL98 AN model with an aim to identify novel small-molecules that might inhibit its 
nuclease activity. We have performed 3D virtual screening on the active site, the results 
of which will be discussed in detail in the following sections.   
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3.2 Methods 
 
3.2.1 Structural Modeling of HCMV UL98 AN 
3.2.1.1 Template Identification and Alignment 
 PSI-BLAST (Position-Specific Iterated BLAST)48,49 was performed on the amino 
acid sequence of HCMV UL98 AN (strain AD169) using the PDB Protein Database to 
identify a template structure based on which its structure can be built. The first Expect 
value (E-value) was set to 1 for the initial BLAST search and the second E-value, which 
is the threshold value for inclusion in the position specific matrix (BLOSUM62) used for 
PSI-BLAST iterations, was set to 0. The Shutoff and Exonuclease Protein from KSHV 
(KSHV-SOX) (PDB ID: 3FHD)45 was chosen as the “template” structure for model 
building, based on its max score of 104 and E-value of 1e-22. Clustal X v2.050 was used 
to align the amino acid sequence of UL98 AN (query sequence) with the sequence of 
KSHV-SOX (template). The active site and the 5’ phosphate binding residues in UL98 
AN were identified based on their alignment with corresponding residues of KSHV-SOX. 
3.2.1.2 Homology Modeling of UL98 AN 
 The homology model of UL98 AN was constructed based on the available crystal 
structure of KSHV-SOX (PDB ID: 3FHD) and the sequence alignment obtained from 
Clustal X v2.0 using Comparative Modeling Program MODELLER 9v7.51-54 MODELLER 
sets up spatial restraints on Cα-Cα distances, main chain N-O distances and main chain 
and side chain dihedral angles obtained from the template crystal structure.51  A total of 
	   79 
100 models were generated using the automodel class of MODELLER, which builds 
models by violating these restraints as little as possible. The final model was selected 
based on its ability to accommodate a DNA fragment in its active site crevice.   
3.2.1.3 Docking of dsDNA into the active site of UL98 AN 
Protein structure preparation. From all 100 generated models, the unaligned 
regions that were built by MODELLER without a template were deleted using the 
general molecular modeling program SYBYL v8.1 (TRIPOS Inc.); i.e., residues Met1-
Glu25, Arg83-Ile90, Thr344-Leu355, Lys381-Ser419, Asp431-Val446, and Ser569-
Pro584. The region starting at Asp189 and ending at Phe211, which is near the active 
site, aligned with ‘the bridge’ region of the template (Pro164-Phe179), which could not 
be crystallized owing to disorder,45 was deleted from the alignment. All the other regions 
that were deleted were distant from the active site crevice of UL98 AN and should not 
affect later modeling in this region. Hydrogens were added to all the protein structures, 
charges were calculated by the Gasteiger-Hückel method, and all models subjected to 
Powell minimization for 1000 steps, keeping the coordinates of all non-hydrogen atoms 
fixed.  
Substrate preparation. A B-DNA dodecamer (PDB ID: 3BNA) was chosen as the 
ligand to be docked into the active site crevice of UL98 AN homology models using 
GOLD v4.1. Since this ligand was too big, a 4bp long dsDNA fragment (A-C-G-T) was 
built in SYBYL v8.1 (TRIPOS Inc.), and used as a reference ligand for docking. The 
positions of the 5’-phosphate group and the phosphodiester bond joining the final two 
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bases as predicted by GOLD, were then used to overlay the corresponding groups of 
3BNA in order to get the final protein-ligand complex.   
  Docking. The ACGT reference ligand was docked into the active site crevice of 
all MODELLER generated UL98 AN homology models using GOLD v4.1. The binding 
site was defined to encompass all atoms within a 15 Å radius of Oδ1 of Asp254, which 
is located at the center of the active site. All rotatable bonds, except terminal, in the 
ACGT reference ligand were fixed to make sure that GOLD would not disrupt the double 
stranded helix structure by rotating the other bonds in the ligand structure to find a 
better binding mode. Default Genetic Algorithm parameters were used. A total of 30 
solutions were generated for each UL98 AN homology model. The solutions for each 
model were scored and ranked using the GOLD Fitness Scoring Function. Only 8 out of 
all the homology models gave positive GOLD Fitness Scores, suggesting that the other 
models were unable to accommodate the ACGT ligand. The binding modes of the 
ACGT ligand in the remaining 8 models were visually analyzed to see which UL98 AN 
model was best able to accommodate the reference ligand and explain its exonuclease 
activity. HCMV UL98 AN homology model065 was chosen, as it was best able to 
accommodate the 5’ phosphate group among all the models. This final model was 
subjected to further refinement. The 5’ phosphate group and P2 group of 3BNA were 
overlaid onto the positions of the corresponding groups in the ACGT reference ligand, in 
its best conformation for UL98 AN model065 as predicted by GOLD, in order to obtain 
the best possible conformation for 3BNA in the active site of UL98 AN.   
	   81 
3.2.1.4 Final UL98 AN Model – Refinement and Validation 
 UL98 AN model065 was evaluated using the DOPE (Discrete Optimized Protein 
Energy) scoring function55 and GA341 assessment score,56 incorporated within 
MODELLER 9v7. A DOPE per-residue score was calculated for this model065 and 
compared to that of the KSHV-SOX crystal structure. 
KSHV-SOX is a PD-(D/E)XK nuclease that uses a magnesium ion and a water 
molecule for activity.45  The relative coordinates of a putative active site magnesium ion 
and water molecule for UL98 AN model were obtained from the crystal structure of 
KSHV-SOX, by aligning their structures based on homology within SYBYL v8.1. 
Model065, now containing active site magnesium ion and water molecule, was 
complexed with 3BNA (in a position analogous to the best conformation of the ACGT 
reference ligand). The side-chain of Ser252 in the active site of UL98 AN was manually 
rotated towards the 5’ phosphate group to show better interaction, mimicking the 
position of the corresponding active site Ser219 of KSHV-SOX. This protein-ligand 
complex was then subjected to Powell Minimization to a gradient of 0.005 kcal mol-1 Å-1 
to account for any steric clashes and to obtain an induced fit model of UL98 AN with its 
substrate. Following minimization, all the ligands were deleted from the protein and 
Ramachandran plots were calculated using MolProbity.57 
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3.2.1.5 Multiple Sequence Alignment of Herpesvirus ANs 
 In order to check that the active site residues identified for HCMV UL98 AN are 
conserved within other Herpesviridae ANs, the primary amino acid sequences for 
Herpesvirus ANs, including Human Cytomegalovirus (HCMV) Alkaline Nuclease UL98, 
ORF37 of Kaposi’s Sarcoma Associated Herpesvirus (KSHV) (ABD28888), BGLF5 of 
Epstein-Barr Virus (EBV) (ABB89261), U70 of Human Herpesvirus 6 (HHV6) (NP-
050249), U70 of Human Herpesvirus 7 (HHV7) (AAC40784) and UL12 of Human 
Herpesvirus 1 (HHV1) (BAA84005) were obtained from the NCBI 
(http://www.ncbi.nlm.nih.gov/) and aligned using Clustal X v2.0.50 
3.2.1.6 Estimation of Changes in Free Energies of Association of UL98 AN with dsDNA 
upon Mutation 
Intermolecular interactions between the UL98 AN and dsDNA (3BNA), in their 
minimized complex form, were calculated using HINT (Hydropathic INTeraction). The 
HINT score (Htotal) was calculated and converted to free energy using the equation: 
ΔGbinding = − 0.00195Htotal − 5.543.58 The structures of mutants of UL98 AN (R164A, 
S252A, D254A, E278A and K280A) were generated within the structure of UL98 –  
dsDNA complex, using SYBYL 8.1 and Htotal scores were calculated for each mutant-
ligand pair, and subsequently converted to ΔGbinding free energy values. On the basis of 
the predicted ΔGbinding for each UL98 mutant, ΔΔGbinding values of differences in free 
energy between wild type and each UL98 mutant were calculated. 
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3.2.2 Validation of UL98 AN Model using Mutagenesis 
 All the experimental work was performed in Dr. Michael McVoy’s lab (Department 
of Pediatrics, Virginia Commonwealth University, VA) and Dr. Deborah S Parris’s lab 
(Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State 
University, OH). For detailed experimental procedures, please refer to our recent 
publication – Kuchta, A., et al.47 Briefly, recombinant UL98 and proteins containing 
single alanine substitutions (R164A, S252A, D254A, E278A or K280A) were expressed 
with amino-terminal hexahistidine (His6) tags. The proteins were expressed and 
partially purified by immobilized metal affinity chromatography (IMAC). The exo 
activities of the IMAC-purified proteins were quantified by release of acid-soluble 
radioactivity from 14C labelled DNA. Endo activity was determined qualitatively by 
incubating IMAC-purified proteins with closed-circular pUC19 plasmid DNA and 
evaluating its conversion to open-circular and linear forms by agarose gel 
electrophoresis. To quantify endo activity independent of exo activity, a fluorescence-
based assay was developed in which fluorescence increases when endonucleolytic 
cleavage of an ssDNA substrate releases a 3’ quencher from a 5’ fluorophore.  
 
3.2.3 3D Virtual Screening on the Active-Site of UL98 AN Model 
 The model of UL98 AN – dsDNA complex was used to identify the important 
molecular interactions involved in the association. These were used as the basis to 
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generate a pharmacophore model describing features desirable in ligands that might 
bind at the active site and inhibit its activity. 
3.2.3.1 Design of Query 
 The UNITY module within SYBYLx1.2 (http://www.tripos.com/) was used to 
create a 3D query that can be used to scan databases of diverse chemical compounds. 
A “negative center”, sphere of 1 Å radius, with the center at a position analogous to the 
5’ phosphate atom, was defined. A “donor atom” feature was defined at a position near 
the catalytic metal, sphere of 0.5 Å radius, such that any hydrogen-bond donor group in 
the ligand would engage the carboxylate groups of D254 and E278 residues and disrupt 
the enzyme’s catalytic activity. Another feature defined in the catalytic region was an 
“acceptor atom”, sphere of 0.5 Å radius, complementary to K280. A central “aromatic 
hydrophobic” core region, sphere of 1.5 Å radius, was defined in the vicinity of the 
deoxyribose ring of the first nucleotide. Next, a distance constraint, with a tolerance of 
±0.5Å, was set up between the negative center and the donor atom. Finally, receptor-
site constraints were defined around heavy atoms of the protein surrounding the cavity. 
 The generated 3D query was used to screen a library of over 250,000 
compounds belonging to the National Cancer Institute Open Database 
(http://cactus.nci.nih.gov/ncidb2.1/). A “flexible 3D search” that uses a torsional 
minimizer was performed. This technique identifies molecules that might fit the defined 
query. Also, all the compounds are screened for their drug-like properties based on 
Lipinski’s rule of five.59 
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 The entire data mining process reduced the candidates to a more manageable 
number, all of which were subjected to docking into the active site of UL98AN. 
3.2.3.2 Docking of Hits 
 The hits obtained at the end of first stage of screening were docked into the 
active site of UL98 AN using GOLD v5.1. This approach leads to identification of hits 
having a better fit in the active site, along with all the structural features necessary for 
binding. Before this step, all the hits were visualized to check for incorrect atom-types, 
bond-types, unsatisfied valencies; all such were corrected if necessary, and saved in a 
ready-to-dock, 3D format. The binding site was defined to encompass all atoms within 
15 Å radius of Oδ1 of Asp254, which is located at the center of the active site. Default 
genetic algorithm parameters were used. A total of 100 solutions per ligand were 
generated (no early termination, no constraints) in order to obtain multiple poses within 
the binding site.  
3.2.3.3 Scoring of Docked Poses 
 To identify the most likely binding mode of a ligand within UL98 AN active site, 
out of all possible solutions generated from docking, each protein-ligand complex was 
scored using the HINT forcefield. Unlike the default scoring function of the docking 
software, HINT scores are known to correlate with the binding free energy.58,60,61  The 
binding modes of the top scored solution for each ligand was visually analyzed. Hits that 
showed significant interaction with the important residues of the active site (R164, S252, 
D254, E278, K280) were retained.   
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3.3 Results and Discussion 
 
3.3.1 The Template – Kaposi’s Sarcoma Associated Herpesvirus Shut-off and 
Exonuclease (KSHV-SOX) 
Herpesvirus ANs are classified within the λ exo family of DNases, which is within 
the PD-(D/E)XK superfamily of DNA-modifying enzymes.43 The catalytic sites of these 
enzymes contain a conserved aspartic acid (D), an aspartic or glutamic acid (D/E) and a 
lysine (K). To identify a potentially related sequence of known structure that can be 
used as a template to build the structure for UL98 AN, PSI-BLAST was performed on 
the primary amino acid sequence of UL98 using the PDB Protein Database. The Shutoff 
and Exonuclease Protein from Kaposi’s Sarcoma Associated Herpesvirus (KSHV-SOX) 
(PDB ID: 3FHD), which belongs to the same PD-(D/E)XK superfamily of proteins, was 
the closest structural match identified, and shares 26% sequence identity and 40% 
homology with it. The catalytic residues of KSHV-SOX are D221 and E244, which 
coordinate Mg2+, and K246, which stabilizes the leaving group.45 An adjacent 5’-
phosphate-binding pocket formed by R139, S146 and S219 was suggested by the 
presence of a sulphate ion in the crystal structure.45 Figure 3.3 shows the overall fold of 
KSHV-SOX and its active site residues. 
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Figure 3.3 – Template structure KSHV-SOX (PDB ID: 3fhd).  
The catalytically important Mg2+ ion (green sphere) and sulfate ion (sticks) at a position 
analogous to 5’ phosphate binding site. The inset shows the active-site residues (shown 
as sticks) that are involved in coordination of sulfate ion and Mg2+ ion. Image prepared 
using PyMOL.62   
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3.3.2 HCMV UL98 AN Model 
 Pairwise sequence alignment between the UL98 AN primary amino acid 
sequence and that of KSHV-SOX was performed using Clustal X v2.0, which helped to 
identify the regions of similarity (Figure 3.4). Amino acids D254, E278 and K280 of 
UL98 AN are the corresponding catalytic residues, and R164, T171 and S252 form the 
putative 5’-phosphate-binding pocket.  
 A structural model of UL98 was constructed based on the crystal structure of 
KSHV-SOX and in silico docking was used to determine the optimal binding of a dsDNA 
dodecamer in the predicted UL98 binding site crevice.  
 A total of 100 models of UL98 AN were generated using the comparative 
homology modeling program MODELLER 9v7, based on the sequence alignment with 
KSHV-SOX. The docking was initially performed using a 4 bp long nucleotide (ACGT) 
as the reference ligand. The most reasonable accommodation of the ligand in the active 
site was shown by model065. The model shows that 5’ phosphate end is held in place 
deep into the active site crevice through strong hydrogen bonding interactions with side 
chains of Arg164 and Ser252 and weak interactions with the backbone of Ala170 and 
Thr171. Also, the phosphodiester bond, where nucleophilic attack takes place for 
hydrolysis, is situated very close to Asp254, Glu278 and Lys280, which is the metal 
coordination site.  
 Model065 was evaluated using the Discrete Optimized Protein Energy (DOPE) 
scoring function and GA341 assessment score within MODELLER 9v7. DOPE per-  
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Figure 3.4 – UL98 AN amino acid sequence in pairwise alignment with KSHV-SOX, 
using Clustal X v2.0.  
Asterisks indicate putative active site residues and the default Clustal X v2.0 color 
scheme is applied. Apparent insertions in UL98 AN relative to KSHV-SOX (lower case) 
and residues that align with a region in KSHV-SOX that did not crystallize (grey box) 
were deleted from the UL98 model. Figure prepared using Jalview,63,64 sequences 
colored using the default Clustal X color scheme (Appendix A.1). 
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residue scores calculated for both model065 and 3FHD indicated that model065 depicts 
UL98 AN in a native-like form, as the two DOPE profiles were similar in the active site 
region. The GA341 method, which uses percentage sequence identity with the template 
as a parameter to assess the quality of the predicted model and ranges from 0.0 (worst-
model) to 1.0 (native-like), yielded a score for model065 of 0.9999.  
The coordinates for a putative Mg2+ ion and active site water molecule for 
model065 were obtained by aligning the template structure to the model. The protein-
ligand complex was then subjected to an all-atom minimization to a gradient of 0.005 
kcal mol−1 Å−1 to account for steric clashes and to obtain an induced-fit model of UL98 
with its substrate. All the ligands were then deleted from the model and Ramachandran 
plots were calculated using MolProbity. 83.1% of the residues were in the favored 
region and 96.8% of residues in the allowed region (Figure 3.5). Out of 438 residues, 
there were 14 outliers; each was visually inspected and all were found to reside in 
regions remote from the active site region.  
 The final UL98 AN structural model was generated following refinement 
(discussed above) on model065. Figure 3.6 shows the overall structural fold of the 
protein, comprising an amino-terminal domain consisting of ten α-helices and a carboxy-
terminal domain formed by five-stranded β-sheets flanked by five α-helices. The 
putative Mg2+ ion and the active-site water molecule are also shown, along with the 
active-site residues. 
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Figure 3.5 – Ramachandran plots for UL98 AN homology model as determined by 
MolProbity. Outliers are shown in colors.  
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Figure 3.6 – UL98 AN Model.  
Active site residues are shown in blue sticks. The catalytically important Mg2+ ion and 
water molecule are shown as spheres. Image prepared using PyMOL.  
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 Guided by the positions of the 5’ phosphate group and the P2 group, the 
structure of crystallized dsDNA (PDB ID: 3BNA) was overlaid on ACGT reference ligand, 
in its best-docked position within the active site crevice of HCMV-UL98. The predicted 
position of DNA shows the 5’ phosphate held deep into the active-site crevice through 
hydrogen bonding with R164 and S252. The scissile phosphodiester bond is 
appropriately positioned proximal to the metal coordination region formed by D254, 
E278 and K280 (Figure 3.7).  
 Important active site residues should be strongly conserved within the 
Herpesviridae ANs. Previous alignments have identified seven amino acid motifs that 
are conserved among ANs from the α-herpesvirus subfamily and extend to ANs from 
the β and γ-herpesvirus subfamilies.65 To determine if the five residues predicted by 
structural modeling are conserved, amino acid sequences for ANs representing all three 
subfamilies were aligned using Clustal X v2.0 (Figure 3.8). The putative active site was 
found to span motifs II and III. Residues Arg164, Ser252, Asp254, Glu278, and Lys280 
were fully conserved. 
Active-site models for DNA interactions of wild-type and mutant UL98 proteins 
were generated from the UL98 model. Fig. 3.9 shows predicted active-site structures for 
wild-type UL98 and each of the five mutants. Loss of hydrogen-bonding interactions 
resulting from substitutions R164A or S252A may result in imprecise alignment of the 
DNA in the active site, resulting in improper positioning of the scissile phosphodiester 
bond relative to the catalytic K280 residue (Figure 3.9(B) and 3.9(C)). This was further 
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Figure 3.7 – UL98 AN active site model (residues – carbons in cyan; dsDNA – carbons 
in green). 
Mg2+ (green sphere) is coordinated by the carboxylate groups of D254 and E278 and 
holds the water molecule (red sphere) at the active site. K280 is proximal to the 
phosphodiester group and the 5’ phosphate shows strong hydrogen-bond interactions 
with side chains of R164 and S252. Image prepared using PyMOL.  
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Figure 3.8 – Multiple sequence alignment between Herpesvirus alkaline nucleases.  
Asterisks indicate active-site residues that are fully conserved among the entire family. Figure prepared using Jalview, 
sequence colored using the default Clustal X color scheme (Appendix A.1).  
 
	   96 
supported by significant changes in the predicted DNA-binding energies for R164A, 
S252A and K280 mutants (Table 3.2). Similarly, the loss of charged carboxylate 
residues in D254A or E278A mutants would result in failure to coordinate the 
magnesium ion and water molecule (Figure 3.9(D) and 3.9(E)). Changes in predicted 
DNA-binding energies for mutants D254A and E278A are minimal (Table 3.2), 
consistent with these residues interacting with Mg2+ rather than by directly interacting 
with the DNA. The K280A mutation would be unable to carry out the hydrolysis of the 
phosphodiester bond and stabilize the leaving group (Fig. 3.9(F)).  
 
 
 
Table 3.2 - HTOTAL scores and corresponding ΔΔGbinding energies calculated for wild-type 
and UL98 AN mutants 
Protein HTOTAL ΔΔGbinding (kcal mol-1) 
WT 5401 0.00 
R164A 3190 4.31 
S252A 4159 2.42 
D254A 5267 0.26 
E278A 5303 0.19 
K280A 3204 4.28 
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Figure 3.9 – Active site models for DNA interactions of wild-type and mutant UL98. 
Active site residues are shown as sticks with carbon atoms in cyan, the DNA is shown 
as sticks with carbons in green. Image prepared using PyMOL. 
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 The region starting at Asp189 and ending at Phe211 in UL98 AN, the bridge 
region that connects the N-terminal domain to the C-terminal domain, was not modeled 
due to its absence in the template owing to disorder. There have been suggestions that 
the bridge architecture plays an important role in exonucleolytic cleavage by inducing 
strand separation.46,66 The bridge region is also proposed to promote endonucleolytic 
processing by developing local regions of ssDNA within the substrate, which are the 
likely targets for endo cleavage. However, the high degree of disorder in the structure of 
the bridge region in both KSHV-SOX and the KSHV-SOX–DNA complex structures 
made it difficult to model the corresponding region in UL98. Thus, our modeling focused 
on the active-site region and cannot be extrapolated to the role of ‘the bridge’ in the 
functions of UL98.  
 
 
3.3.3 Validation of UL98 AN Model using Mutagenesis 
 The experimental data are generally consistent with the modeling predictions. 
For details, please refer to our recent publication – Kuchta, A., et al.47 
 All of the single-alanine mutant proteins failed to digest substantial amounts of 
substrate DNA in a one hour period. Exo activity of the R164A mutant was 10.6% of 
wild-type and statistically higher than those of the other mutants and GUS (negative 
control); whereas activities for D254A, E278A, K280A and S252A were <5% that of 
wild-type and not statistically different from each other or from GUS (Figure 3.10). 
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 For the D, E or K è A mutants, endo activity was greatly reduced, but low level 
activity was still apparent with the supercoiled dsDNA substrate. Although D254A and 
E278A preparations were able to convert some of the supercoiled DNA into open-
circular and full-length linear DNA, the majority of the supercoiled DNA substrate 
remained intact after the 12 hour incubation. In contrast, the K280A and S252A mutant 
proteins nicked essentially all of the supercoiled DNA, although large amounts of nicked 
open-circular and full length linear forms remained undigested. Following 12 hour 
incubation, the wild-type and R164A proteins were not only capable of nicking the 
supercoiled substrate, they had degraded all of the DNA substrate, presumably to 
products too small to visualize on the gel.  
 The quantitative fluorescence-based assay showed no significant difference 
between the endo activities of R164A and wild-type UL98 and both wild-type and 
R164A endo activities were significantly different from those exhibited by GUS and the 
other mutant proteins. The activities of S252A, D254A or E278A were not different from 
each other or from GUS (Figure 3.11). 
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Figure 3.10 – UL98 AN mutants – Exo activity.  
(a) Exo activities were determined as acid-soluble radioactivity released during 
incubation of 14C-labelled DNA with 2.5 µg of IMAC-purified UL98 WT or UL98 R164A. 
(b) Exo activities of mutants were measured after one hour incubation. Data are means 
of disintegrations per minute obtained from three experiments. Error bars represent 
means ±1 SD. 
* R164A differs from GUS and other mutants; unpaired t-test, P ≤ 0.05  
Reprint from ref 47. 
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Figure 3.11 – UL98 AN mutants – Endo activity. 
 (a) Supercoiled plasmid DNA (250 ng) was incubated for 12 hours with buffer only (ϕ), 
5 µg of IMAC-purified protein of 1 U of DNase I. Products were analyzed by agarose gel 
electrophoresis. Arrows indicate the positions of supercoiled (SC), open circular (OC) 
and linear (L) DNA.  (b) A 35 nt synthetic ssDNA substrate with a fluorescent emitter at 
the 5’ end and a quencher at 3’ end was incubated for 14 hours with increasing 
amounts of each protein; fluorescence was measured as relative fluorescence units 
(RFU). 
Reprint from ref 47.  
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 The estimation of changes in free energies of association between UL98 AN and 
ds DNA upon mutation using HINT (refer section 3.3.1.7) predicts that D, E or K è A 
substitution mutants should lack both exo and endo activity and that R or S è A 
mutants may have impaired exo activity. As no 5’ phosphate is present on the substrate 
in endonucleolytic cleavage, endo activity might be unaffected in R or S è A mutants. 
Consistent with this, we observed experimentally that the D, E or K è A mutants lacked 
measureable exo activity. Endo activity was greatly reduced, but low-level activity was 
still apparent with the supercoiled dsDNA substrate. Of the two UL98 mutations 
targeting putative phosphate-binding residues, R164A behaved as predicted. Exo 
activity was reduced by 90%, but there was no impact on endo activities detected with 
supercoiled dsDNA or end blocked ssDNA substrates. In contrast, the S252A mutation 
eliminated exo activity, and reduced both ssDNA and supercoiled dsDNA endo activities 
to levels similar to those of the K280A mutant. We believe that the proximity of the S è 
A mutation, one residue from the catalytic aspartic acid, may have perturbed the local 
geometry of the active site enough to impair catalytic function, and hence to have 
impacted not only exo but also endo activity. 
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3.3.4 3D Virtual Screening Hits 
 We have performed a virtual screening study on the active site of UL98 AN for 
possible identification of its novel inhibitors. The model of UL98 AN complexed to 
dsDNA, validated by mutagenesis, identified important residues in the enzymes’ active-
site. Based on the interactions of the 5’ phosphate group and the scissile 
phosphodiester group in the active site of UL98 AN, it was clear that negatively charged 
groups were desirable in the ligand. The model also helped predict other electronic and 
structural features that would appear to be necessary for a molecule to bind at the 
active site. 
A pharmacophore model describing molecular features that are necessary for 
recognition by the enzyme was generated. One of the important features in the active 
site of the enzyme is the anionic site formed complementary to the side chains of R164 
and S252, which accommodates the 5’ end phosphate group of DNA. This site was 
defined as a “negative center” in the query. The second feature defined was a “donor 
atom” feature in order to look for a hydrogen-bond donor group in the ligand, capable of 
interacting with the carboxylate groups of D254 and E278. An “acceptor atom” was 
defined in the vicinity of K280, with an aim at engaging the amino group that is 
important for stabilizing the leaving group of substrate. The central hydrophobic 
aromatic core was defined to impart rigidity to the molecule. A larger region was defined 
so that compounds with bicyclic and tricyclic aromatic scaffolds can also be identified as 
hits. Also, an aromatic scaffold affords synthetic ease during compound modifications at 
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the stage of lead optimization. A distance constraint was set up between the two 
features for better defining the 3D shape of the cavity and to eliminate many 
undesirable compounds. Receptor site constraints were set up around the atoms 
surrounding the cavity, in order to avoid steric clashes. The compounds VDW volume 
must not intrude into these exclusion spheres to be considered a hit. The final three-
dimensional query is shown in Figure 3.12. 
The compounds in NCI Open Database were screened against the 
pharmacophore model using the “flex search” algorithm within UNITY. This algorithm 
generates all possible conformations of a given candidate structure, performs 
minimization in torsion angle space, and attempts to determine if it can reasonably flex 
into a conformation that matches the query.67 The compounds were also checked 
against the pre-defined set of rules, Lipinski’s Rule of Five (that gives a molecule 
favorable permeation and absorption characteristics), viz. the molecule should have 
less than 5 hydrogen-bond donors and 10 hydrogen-bond acceptors, its molecular 
weight should be less than 500 D and its ClogP less than 5. 
The process of virtual screening narrowed down the number of compounds from 
~250,000 to a more manageable number of 72. All these ‘hits’ were docked into the 
active site of UL98 AN, and the docked poses were rescored using HINT. The best 
binding mode of each compound, based on HINT scores, was analyzed visually to 
identify a reasonable binding in the active site such that the catalytically important 
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Figure 3.12 – Pharmacophore Model.  
Negative-center (radius 1 Å) showed as red sphere, donor-atom (radius 0.5 Å) showed 
as cyan sphere, acceptor-atom (radius 0.5 Å) showed as red sphere, aromatic 
hydrophobic center (radius 1.5 Å) showed as green sphere. Distance constraint (±0.5 Å) 
set up between negative-center and acceptor-atom. Purple spheres are the receptor-
site constraints.  
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residues would be engaged. Table 3.3 / Figure 3.13 shows the list of top 15 chemically 
diverse compounds identified as “hits”, along with their NSC numbers and HINT scores. 
 Figure 3.14 shows compound NSC 120634, which is the second best scored 
compound, within the active site of UL98 AN. Even though NSC 238165 had a higher 
score, NSC 120634 showed perfect fit into the pharmacophoric model, satisfying all the 
features defined to be desirable in a candidate structure. Also, its binding mode predicts 
interactions with all the catalytically important residues, D254, E278, K280, as well as 
those involved in 5’-phosphate-binding, R164 and S252.  
All compounds listed in Table 3.3 were obtained from the NCI and are currently 
being evaluated for their exonuclease and endonuclease inhibitory activity. Suitable 
candidates shall also be evaluated for their antiviral activity in cell culture and for toxicity. 
Some of these compounds have HINT scores significantly higher than that of dsDNA in 
the active site (refer Table 3.2), and hence might be expected to be stronger binders of 
UL98 AN. 
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Table 3.3 – Top 15 hits from virtual screening (ranked based on HINT scores) 
Rank NSC # HINT Score 
1 NSC 238165 9665 
2 NSC 120634 8171 
3 NSC 175852 6639 
4 NSC 342023 6259 
5 NSC 60279 5975 
6 NSC 37413 5283 
7 NSC 37053 5210 
8 NSC 163 4670 
9 NSC 226640 3943 
10 NSC 132073 3582 
11 NSC 163091 3510 
12 NSC 44630 2900 
13 NSC 129478 2880 
14 NSC 329204 2747 
15 NSC 41439 2656 
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Figure 3.13 – Structures of virtual screening hits (top 15)  
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NSC 120634 
5-(hydrazinylsulfonyl)isophthalic acid 
 
Figure 3.14 – Binding mode of hit NSC120634.  
The carboxylates of isophthalic aromatic nucleus shows strong salt-bridge interactions 
with guanidine- and amino- groups of side chains of R164 and K280 respectively, 
occupying positions analogous to the phosphate groups of DNA substrate. The 
hydrazine moiety shows strong interactions with the carboxylate groups of D254 and 
E278.  
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3.4 Conclusion 
 In the absence of a crystallographic structure for UL98 AN, in silico modeling was 
used to successfully build a structural model of the protein that predicted the residues 
important for its nucleolytic functions. The predicted active-site residues – R164, S252, 
D254, E278 and K280, were validated by mutagenesis, where alanine scanning showed 
abolition of activity. Identification of residues involved in 5’-phosphate binding that affect 
the exo, but not the endo activity, may provide a useful tool for exploring the biological 
roles of each activity in herpesvirus replication.  
 The structural model provided a basis for performing rational drug discovery to 
identify novel antiviral agents for CMV infections. A virtual screening for active site 
inhibitors of UL98 AN was conducted on a pharmacophore, built based on our model, 
followed by molecular docking and HINT scoring. We have identified a number of novel 
scaffolds that have shown promise in our computational studies. These candidates are 
currently being evaluated experimentally.   
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CHAPTER 4 
INCLUSION OF “RELEVANT” INTERFACIAL WATERS IMPROVE PROTEIN-
PROTEIN DOCKING PREDICTIONS 
 
 
 
4.1 Introduction 
 
4.1.1 Protein-Protein Interactions: Need for Computational Prediction Tools 
 Protein-protein interactions play a fundamental role in most biological events and 
many pathological processes. Virtually every molecular process in a cell is carried out 
via interactions between two macromolecules; for example, DNA synthesis, gene 
expression, post-translational modifications, transport, signal transduction, etc. Various 
genetic, biochemical, or bioinformatics studies have identified tens of thousands of 
proteins interacting with each other forming millions of putative complexes. A detailed 
atomic understanding of the nature of these often-transient interactions is a key step to 
exploiting/inhibiting these biomolecular associations as potential new routes to disease 
therapeutics. 
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A large number of datasets exist that contain experimentally verified protein-
protein interactions, like HPRD (Human Protein Reference Database),1 BIND 
(Biomolecular Interaction Network Database),2 MINT (Molecular Interactions 
Database),3 etc. These databases contain a total of about 26,500 binary protein-protein 
interactions,4 and provide a wealth of information pertaining to the human proteome. 
These data are related to thousands of protein-protein interactions, post-translational 
modifications, enzyme/substrate relationships, disease associations and more. 
 In contrast, the RCSB Protein Data Bank (http://www.rcsb.org/pdb/) only contains 
a few hundred protein-protein complex structures. One of the reasons for this lack of 
structural information is that experimental structural determinations using techniques 
like X-ray crystallography, Nuclear Magnetic Resonance (NMR) and Electron 
Microscopy (EM) are very demanding.5 
 During the past couple of decades, there has been a rapid emergence of novel 
computational algorithms to predict, model and understand these interactions – also 
known as protein-protein docking methods. These predictive methods have been very 
essential for progress, since the experimental structural determination techniques, 
although powerful, definitely have low throughput. Accurate and reliable computational 
predictions are very useful in inferring how two proteins bind, give valuable functional 
information about the interacting proteins and also help guide new genetic and 
biochemical experiments.  A number of docking algorithms and different scoring 
functions have been developed in recent times, and this endeavor has gained wide 
popularity as seen by the CAPRI (Critical Assessment of PRedicted Interactions), a 
communitywide experiment.6 Wodak and Janin were the first to develop a predictive 
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algorithm, in the late 1970s that generated possible orientations of one protein relative 
to another.7 
 
4.1.2 Protein-Protein Docking: The Process 
As the field developed, protein-protein docking algorithms have become more 
sophisticated partly due to the rapid progress in computer hardware, but also due to our 
improved understanding of structure and interactions. The docking protocols have 
evolved from simple rigid-body docking (where both interacting partners are considered 
as rigid solid bodies), to soft-body docking (which incorporates side-chain and backbone 
flexibility in either one or both molecules), to inclusion of short MD simulations (to obtain 
an induced-fit model), to inclusion of explicit solvent models within their docking 
protocols; all of which are probably directly attributed to the availability of increased 
computational power. 
 The process of docking macromolecules is multi-step, involving accurate 
representation of the system, conformational space search, protein flexibility upon 
association and ranking of potential solutions.8 
 In most of the current docking approaches, the description of the protein surface 
is the atomic representation of its solvent-exposed residues, using mathematical models 
such as geometric shape descriptors like the Connolly surface.9 The geometric 
descriptors that accurately represent the maxima (holes) and the minima (knobs) of the 
shape function10,11 are usually combined with other computed properties designed to 
have physicochemical meaning like the affinity grids that are calculated based on the 
force field potentials for Van der Waals and electrostatic interactions.12 Precise 
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representation of the system is followed by a search of the available conformational 
space. The majority of programs employ an “ab-inito” approach: one of the docking 
partners (usually the larger one) is fixed in space and the second protein is rotated and 
translated around the fixed one. Different search methods have been used: matching 
surface complementarity at the protein-protein interface;13 combining geometric 
complementarity with amino acid pairwise affinities at the interface;14 Fourier correlation 
techniques such as the FFT algorithm, first described by Katchalski-Katzir et al.,15 which 
evaluates the interface contacts between binding partners while penalizing protrusions 
into the protein core. Other algorithms like geometric hashing,10,16-18 Genetic 
algorithms,19 Brownian dynamics simulations,20 and simulations combined with energy 
minimization21 have also been applied to the docking problem. 
 The induced fit model suggested by Koshland shows that conformational 
changes could occur upon binding.22 A variety of studies followed that supported this 
theory of flexibility. It is impractical to treat molecular flexibility in an explicit way in the 
case of protein-protein docking, due to the large number of atoms and degrees of 
conformational freedom involved. However, a number of approaches have tried to 
address this shortcoming. A recent review by Andrusier, et al. describes how protein 
flexibility is treated during different stages of the docking process.23 Some docking 
protocols adopt a two-stage approach that combines rigid-body search with molecular 
dynamics to account for backbone and/or side-chain flexibility. Side-chain optimization 
has been shown to discriminate near-native conformations from false positives.24 
Another algorithm, SOFTSPOTS identifies interfacial residues most likely to undergo 
conformational change at an interface, and generates the corresponding rotamers, 
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before the docking calculations.25 Incorporating full backbone flexibility is highly 
challenging, because too large a conformational change in a backbone may lead to 
deformation of global structure. Various docking methods handle backbone flexibility 
differently – some methods utilize “soft docking” protocols that initially allow steric 
clashes, followed by a refinement step; some perform ensemble docking, using different 
conformations generated a priori; some methods deal with hinge-bending motions, while 
other methods perform a wide conformational space search to identify energetically the 
most favorable one.23 
 Comprehensive search algorithms generate a huge number of potential solutions, 
from which the one corresponding to the lowest free energy of binding must be found. 
An ideal scoring function should be able to distinguish between native-like predictions 
from false-positives. During the complex prediction step, the degree of shape 
complementarity of the interacting protein surfaces is used as an initial filter to eliminate 
incorrect predictions; but that alone is not sufficient to take into account the complete 
energetics of protein-protein associations. In most of the algorithms developed so far 
the initial filtering is then followed by ranking the predicted solutions using scoring 
functions that take into account geometric complementarity, electrostatic interactions, 
hydrogen bonding and/or desolvation energy.26-28 Most scoring functions are designed 
to predict the free energy of binding ΔGbinding, which is not a trivial task, since the 
individual components within them are imperfectly able to completely characterize the 
biomacromolecular association process.12 Despite efforts to identify the correct binding 
modes using free energy as a reliable guide, scoring still remains a major challenge in 
the docking process. 
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4.1.3 Current Protein-Protein Docking Algorithms 
 With the emergence of novel docking approaches to predict biomacromolecular 
associations, a community-wide experiment to evaluate their capabilities was designed 
– called CAPRI (Critical Assessment of PRedicted Interactions).6 CAPRI is a data-
driven blind experiment wherein participating groups submit predictions of a target 
complex using their docking algorithms. The experiments would start when an 
unpublished X-ray crystal structure or NMR structure of target protein-protein or protein-
DNA complex is made available by experimentalists to the CAPRI management. The 
atomic coordinates of the interacting partners are provided to participating structural 
biologists, who within 4-6 weeks, submit a set of 10 models that are compared to the 
experimental structure. The quality of the submitted models is evaluated based on the 
standard CAPRI criteria (that will be discussed in detail in Section 4.2.4) and classified 
as models of “high”, “medium” and “acceptable” accuracy.29 
 The most recently concluded 4th CAPRI Evaluation Meeting held at Mare 
Nostrum, Barcelona (2009) evaluated rounds 13-19 that took place over a period of 
2007-2009 and comprised a total of 14 targets. 76 participating groups submitted a total 
of 4420 docking predictions.30 Rounds 1-2 of CAPRI with a total of 7 targets were 
evaluated in 2002, rounds 3-5 with a total of 10 targets were evaluated in 2005, and 
rounds 6-12 with a total of 9 targets were evaluated in 2007.6,29,31 Each evaluation 
round has been well reported in special issues of the journal Proteins: Structure, 
Function and Bioinformatics (Proteins 2003:52; Proteins 2005:60 and Proteins 2007:69). 
 The comparison of various docking programs based on their relative 
performance in the CAPRI experiments over the last decade is very difficult since the 
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algorithms differ in the methods used to perform the conformational search and score 
the predictions, and may perform better for different types of targets. A recent review on 
protein-protein docking by Moreira, I. S. et al.12 analyzed the performance of the 
participants by giving quantitative measures to the quality of submitted models for each 
target. 
 Globally, ICM-DISCO,32 ZDOCK,28 HADDOCK33,34 and RosettaDock27 have been 
the best predictors over the past decade. The same review article also compares the 
popularity of these programs based on the citations per year, which suggests that the 
most popular ones are HADDOCK,33,34 RosettaDock,27 ClusPro35 followed by 
PatchDock36 and ZDOCK.28 Table 4.1 summarizes the software characteristics, along 
with some advantages and disadvantages, of the top 5 programs (based on their 
performance in the CAPRI experiments and software popularity). 
 
4.1.4 Solvated Docking 
 Water is a vital component in all living organisms and plays a crucial role in all 
biological processes. Particularly for proteins, the dynamics of water-protein interactions 
govern various molecular phenomena – like protein folding and molecular recognition,37 
as well as maintenance of structural integrity.38 A water molecule can act both as a 
donor and as an acceptor of hydrogens, capable of forming four directional hydrogen 
bonds. This allows for easy and rapid reorientation and reconfiguration into different 
three-dimensional structures. Due to this unique property of water, the strongly bound or 
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Table 4.1 – Protein-Protein Docking Softwares: Characteristics, advantages and disadvantages (adapted from ref 12) 
Software Conformational Search Algorithm 
Filtering at search 
stage 
Flexibility 
Search stage Refinement stage 
ICM - DISCO  
(Docking and 
Interface Side-Chain 
Optimization) 
Rigid Body Docking; pseudo-
Brownian Monte Carlo 
minimization  
Specific filtering criterion 
on a case-by-case basis 
– Fully-flexible 
interface ligand side-
chains 
ZDOCK Rigid body search using Fast 
Fourier Transform (FFT) 
algorithm 
Biological data driven-
docking. Allows definition 
of interfacial and blocking 
residues 
– Optimizes full atoms 
internal energy and 
vdW 
HADDOCK                  
(High Ambiguity 
Driven protein-protein 
DOCKing) 
Three stage process - (i) 
randomization of orientations 
and rigid-body energy 
minimization (EM), (ii) semi-
rigid simulated annealing in 
torsion angle space (TAD-SA),      
(iii) refinement in Cartesian 
space with explicit solvent 
Data driven docking - 
Use of chemical shift 
perturbation data and 
NOEs/RDCs data from 
NMR experiments  
Interfacial 
side-chain 
flexibility 
Side-chain and 
backbone flexibility 
in the simulated 
annealing and 
minimization stages 
RosettaDock Rigid-body Monte Carlo 
search followed by 
minimizations 
– Side chain 
minimizations 
– 
ClusPro Rigid body search using Fast 
Fourier Transform (FFT) 
algorithm 
Filtering using empirical 
free energy functions 
– – 
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Table 4.1 – Protein-Protein Docking Softwares: Characteristics, advantages and disadvantages (cont.) 
Software Scoring Advantages Search stage Refinement stage  
ICM - DISCO  
(Docking and 
Interface Side-Chain 
Optimization) 
Truncated vdW potential, 
Electrostatic potential 
corrected for solvation, 
hydrogen-bonding 
potential, hydrophobicity 
potential 
Truncated vdW potential, 
Electrostatic potential 
corrected for solvation, 
hydrogen-bonding potential, 
hydrophobicity potential, 
rotamer probability 
Global procedure, fully-
automated, handles 
induced changes of 
interface side-chains 
ZDOCK Pairwise shape 
complementarity (PSC) 
PSC, desolvation and 
electrostatics 
Performed effectively for 
antibody-antigen test 
cases in CAPRI 
experiments 
HADDOCK                  
(High Ambiguity 
Driven protein-protein 
DOCKing) 
Clustering, based on 
intermolecular energies 
Average interaction energies 
(Sum of electrostatic 
potential, vdW potential, 
ambiguous interaction 
restraints AIR derived from 
experimental information 
available) and Average 
buried surface area  
Side chain and backbone 
flexibility, use of 
experimental data 
restraints narrows the 
space search to relevant 
regions 
RosettaDock Residue-residue 
interaction potential 
van der Waal's potential, 
desolvation potential, 
hydrogen-bond potential, 
electrostatics 
Protocol mimics the 
physical process of 
docking, with refinement 
stage optimizing the 
interfacial side-chain 
packing 
ClusPro Shape complementarity, 
desolvation and 
electrostatics 
Shape complementarity, 
desolvation and 
electrostatics 
Fully-automated program, 
performs docking, filtering 
and scoring rapidly 
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Table 4.1 – Protein-Protein Docking Softwares: Characteristics, advantages and disadvantages (cont.) 
Software Disadvantages Web address References 
ICM - DISCO  
(Docking and 
Interface Side-Chain 
Optimization) 
Less successful for 
cases with significant 
backbone 
rearrangements 
http://www.molsoft.com/docking.html 32 
ZDOCK Ineffective for cases 
with large 
conformational change 
http://zlab.bu.edu/zlab/index.shtml 28 
HADDOCK                  
(High Ambiguity 
Driven protein-protein 
DOCKing) 
(i) Ineffective in cases 
without additional 
experimental data, (ii) 
highly dependent on 
accuracy of biological 
information available a 
priori 
http://www.nmr.chem.uu.nl/haddock/ 33, 34 
RosettaDock Less successful for 
cases with significant 
backbone 
rearrangements 
http://graylab.jhu.edu/docking/rosetta/ 27 
ClusPro Cannot introduce 
additional information to 
drive correct docking 
http://cluspro.bu.edu/home.php 35 
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“conserved” waters (those that are consistently observed in several crystallographic 
structures and not easily displaced by ligands) are capable of modifying the protein 
surface properties like its shape and charge. 
 Even though Bogan and Thorn (1998) proposed an O-ring hypothesis for 
interfaces claiming that occlusion of solvent by hot spot residues is found to be a 
necessary condition for energetically favorable interactions,39 the abundant presence of 
water at protein-protein and protein-DNA interfaces underscores the vital role played by 
water in the polar interactions that stabilize the complexes.40 Jannin’s closer 
examination of structural data on protein-protein and protein-DNA recognition sites 
revealed that the associated interfaces contain at least as many water-mediated 
interactions as direct hydrogen bonds or salt bridges.40  
Some research groups have made efforts to incorporate water-molecules in 
protein-ligand docking protocols, both explicitly and implicitly. The very first hurdle in this 
effort is the determination of bound water molecules at the ligand binding site. Several 
methods available for identifying/predicting protein-ligand interfacial waters have shown 
promise. GRID41 performs well in predicting ligand-binding site water molecules, by 
calculating interaction energy using Lennard-Jones potential, electrostatic and 
hydrogen-bond terms. AQUARIUS,42 a knowledge-based approach, identifies water 
sites in proteins from the experimentally generated electron density maps. CS-Map 
predicts the most favorable binding position of water molecules on protein surface 
based on an interaction potential that accounts for van der Waals, electrostatic and 
solvation contributions.43 The Fold-X force field allows the prediction of positions of 
bound water molecules that show interaction with two or more polar atoms of proteins.44 
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A more recently available tool WaterMap,45,46 predicts active-site bound water 
molecules by solvating the site and calculating its thermodynamic properties. A few 
protein-ligand docking programs like Flex-X,47 Autodock,48 GOLD,49 and GLIDE50,51 
have shown significant improvements in docking performances by developing 
algorithms to include contributions from interfacial waters.52  
All these approaches have shown a lot of promise in protein-ligand systems; 
however, water has been neglected in almost all protein-protein docking algorithms. 
Most of the development in solvated protein-protein docking has been focused on 
implicit treatment of solvent molecules, as it reduces the computational cost associated 
with explicit treatment. Chen et al.53 have reviewed the progress from in-vacuo to in-
solution docking, using implicit solvent-based methods. Although promising, a more 
detailed understanding of a protein-protein complex interface can perhaps be achieved 
from explicit treatment of water molecules. HADDOCK is one of the few docking 
programs designed to account for explicitly added water molecules in the docking 
process. Its solvated docking protocol starts with hydrating individual protein molecules, 
followed by rigid-body docking process resulting in a water layer in between the two 
proteins. All non-interfacial water molecules are then removed and a fraction of resulting 
interfacial waters is subsequently removed in a biased Monte Carlo procedure based on 
water-mediated contact probabilities. This methodology resulted in noticeable 
improvements both in quality and scoring than unsolvated docking, for most of the 10 
studied cases that included examples of both wet and dry interfaces.54 
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4.1.5 Explicit Hydropathic Approach  
 Our lab, led by G. E. Kellogg, along with our collaborators have been interested 
in understanding the energetic contribution of water molecules in various biological 
environments. The empirically derived HINT forcefield (described in detail in Section 
1.5), which models both hydrophobic and polar non-covalent interactions between two 
molecules, forms the basis for our analyses. 
 In a study on five β37 mutant hemoglobin crystal structures, Burnett et al. 
showed the contribution of crystallographically important water molecules in the dimer-
tetramer assembly.55 Fornabaio et al. developed an approach based on HINT energy 
function to map the energetics of water-protein and water-ligand interactions at protein-
ligand interfaces. They analyzed the protein-ligand interactions in the active site of 23 
HIV-1 protease-ligand complexes and showed significant improvement in correlation 
between HINT scores and experimentally determined binding constants when 
appropriate bridging water molecules are taken into account.56 
 In another study by Amadasi et al., protein-water and water-ligand interactions in 
the binding site of sets of uncomplexed and ligand-complexed proteins were evaluated 
using the HINT forcefield.57 Also, each water molecule was scored using the Rank 
algorithm,58 which assigns a higher rank to a water molecule that is capable of a 
maximum of four hydrogen-bonds (≤2 donors and ≤2 acceptors). The HINT free energy 
scoring model and the Rank algorithm were combined to develop a statistically 
validated Water Relevance Metric59 that classifies water molecules in protein binding 
sites that are generally conserved (between unliganded and ligand-bound states) as 
“Relevant” waters. These high Relevance waters are not likely to be displaced by the 
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ligand and should be explicitly considered when building geometrically and functionally 
correct models of the binding site. This also has implications in structure-based drug 
design, as it helps to identify key polar interactions within a protein’s binding site that 
can be utilized to design more potent ligands with polar functional groups capable of 
mimicking water’s hydrogen bonds. 
Spyrakis et al. calculated HINT interaction scores for 39 crystallographic protein-
DNA complexes, taking into account the contributions from interfacial waters that act as 
linkers between amino acid side-chains and nucleotide bases. The study quantified the 
key energetic role of bridging waters in protein-DNA associations.60 Recently, Ahmed et 
al. performed a comprehensive study on the role of bound water at protein-protein 
interfaces.61 Analysis of a total of 4741 water molecules at the interface of 179 
heterodimeric protein-protein complex crystal structures revealed that 21% of the bound 
water is involved in bridging interactions with both proteins. Their analysis also showed 
that the total energetic contribution of bridging water ranges up to -11.35 kcal mol-1 per 
protein pair. Another, more subtle, role that these bridging waters serve at the interface 
is act as nano-scale pH buffers owing to their ability to easily swap between acting as 
hydrogen-bond donors and acceptors and thus maintain the integrity of the interface. 
This comprehensive study emphasized the importance of characterizing the behavior of 
biological waters as their presence at the interface may influence the assembly of 
biomacromolecular complexes, and begins to establish a basis for including the effects 
of individual waters in macromolecular docking algorithms. 
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4.1.6 Specific Aims 
Protein-protein interactions involved in various biological pathways can be 
exploited as novel targets for rational drug discovery. A detailed atomic level 
understanding of interactions at protein-protein interfaces is crucial to identify hot-spot 
residues guiding their recognition. In the absence of experimentally determined 3D 
structure of a protein complex, a docking algorithm aims at predicting it starting from 
atomic resolution structures of the individual components. Although the challenges 
remain significant, different tools for protein-protein docking have been reasonably 
successful at modeling biomolecular associations, as seen from the recent CAPRI 
evaluation.30 Overall, 67% of the participating groups produced acceptable models for at 
least one target. No evident correlation was seen between the ranks of models and their 
accuracy,62 underscoring again the weakness of current scoring function methodology. 
Several studies in our lab, including Chapter 2 and Chapter 3 of this work, have 
successfully shown the utility of the HINT paradigm in calculations of free-energy of 
binding for protein-ligand complexes56,63,64 as well as protein-DNA complexes.65 The 
Computational Titration (CT) algorithm, based on HINT force field, is capable of 
exploring the protonation states of protein active site residues and ligand functional 
groups.66,67 The Water Relevance metric59 has been shown to accurately (92% in cases 
with ≤2.0 Å resolution) predict the conserved water molecules at protein-ligand 
interfaces based on only the unliganded protein structure. It is our current long-range 
goal to incorporate HINT force field along with these tools into a protein-protein docking 
algorithm. While the process of docking is principally a two-stage search and score 
problem, the HINT-based tools can initially be applied easily in the latter stage of 
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complex refinement and scoring. We believe that a protein-protein docking algorithm 
accounting for not only the physical effects of biomolecular association like shape 
complementarity and residue flexibility, but also the associated chemical effects like 
hydropathic complementarity, correct residue ionization states and explicit inclusion of 
interfacial water molecules will yield more realistic models, but these effects must be 
incorporated during the search stage and will be reported in other reports from our 
laboratory. The current work addresses the issue of explicit solvent accounting during a 
protein-protein docking process. 
In this study, we investigate the effect of bridging waters on docking performance. 
ZDOCK, a rigid-body protein-protein docking program, was used for the purpose of this 
study, as it has consistently been a top performer at the CAPRI experiments.12 The 
main aim of this project was to check the influence of explicit water accounting on the 
accuracy of predictions, and not necessarily to improve upon the current ZDOCK 
algorithm. Interfacial waters relevant to both interacting partners were identified using 
the HINT Relevance metric. We forced ZDOCK to include these waters as atoms in one 
of the two interacting proteins, and show that more accurate results are obtained when 
water is not ignored. 
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4.2 Methods 
 
4.2.1 Data Set 
 A non-redundant benchmark for protein-protein docking algorithms, which 
contains test cases for which the 3D structures of the complex and both unbound 
components are available, was developed by Weng’s group at University of 
Massachusetts.68 To obtain a set of well-structured interfacial waters, the data set for 
this study was limited to those cases for which the bound complex resolution is ≤ 2.0 Å.  
The coordinates for all the complexes in our data set were obtained from the 
Protein Data Bank (http://www.pdb.org/). First, all ligands and cofactors were deleted 
from each complex structure using SYBYL v8.1 (TRIPOS, Inc.). For cases with “multi”-
mer assembly, only one chain of each component forming the complex was retained. 
Hydrogen atoms were added and minimized under the Tripos force field (1000 iterations, 
0.01 kcal mol-1 Å-1 gradient, Gasteiger-Hückel charges), keeping the coordinates of all 
heavy-atoms fixed. Interfacial waters, those that are within 4 Å from atoms on both 
interacting proteins, were retained with each protein-protein complex. For each test 
case, the larger protein of the two was defined as the “receptor” protein, which would be 
kept fixed during the docking process, and the smaller one as the “ligand” protein.  
 
4.2.2 Determination of “Bridging” Interfacial Waters – 
 Intermolecular interaction score was calculated between each receptor-ligand 
pair using HINT scoring function.69 In principle, the HINT model scores each atom-atom 
interaction (𝑏!") between atoms i and j using –  
	   133 
 𝑯𝑻𝑶𝑻𝑨𝑳 =   𝚺𝒊𝚺𝒋𝒃𝒊𝒋 =   𝚺𝒊𝚺𝒋 𝒂𝒊𝑺𝒊𝒂𝒋𝑺𝒋𝑻𝒊𝒋𝑹𝒊𝒋 +   𝒓𝒊𝒋  (1) 
where, a is the hydrophobic atom constant, S is the solvent accessible surface area, Tij 
is a logic function assuming +1 or -1 value depending on the character of the interacting 
polar atoms, and the distance dependent functions Rij and rij are simple exponential 
function e-r and an implementation of the Lennard-Jones potential function,70,71 
respectively. A direct HINT interaction score was calculated for every protein-protein 
complex, without accounting for the contributions made by interfacial waters. The HINT 
parameters and controls used were similar to those in the previous studies57,60,65 – the 
protein molecules were partitioned using the dictionary method, with essential hydrogen 
treatment (where polar hydrogens are treated explicitly and non-polar ones are treated 
implicitly), and a 30 Å2 correction used for calculations of the S-values for backbone 
amide nitrogens.  
 Next, the crystallographic orientation of every water molecule at the interface was 
optimized using an algorithm that performs an exhaustive search of its orientation space 
to assign H-atom positions.72 This algorithm, developed around the HINT empirical force 
field, treats every water molecule as a ‘small-ligand’ and the surrounding atoms (within 
6-8 Å) from both proteins as its ‘binding-site’. HINT scores are calculated between the 
water molecule and its surroundings, allowing rotation of H-atoms around the three axes 
and limited translation of O-atom centroid with an aim at maximizing the interaction 
score. 
The Rank algorithm72 was applied to the optimized water molecules. Ideally, a 
water molecule is capable of forming a maximum of four hydrogen-bonds (≤2 donors 
and ≤2 acceptors) with its surrounding atoms. Rank represents the weighed number of 
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potential hydrogen bonds that each optimized water molecule forms, and is calculated 
as shown 
 𝑹𝒂𝒏𝒌 = 𝚺𝒏 𝟐.𝟖𝟎  Å/𝒓𝒏 + 𝚺𝒎  𝒄𝒐𝒔 𝜽𝑻𝒅 −   𝜽𝒏𝒎 /𝟔    (2) 
where, rn is the distance between the water O-atom and target heavy atom atom n (n = 
1 to number of valid targets), θTd is the ideal tetrahedral angle (109.5°) and θnm is the 
angle between targets n and m (n = m to number of valid targets). The Rank algorithm 
yields values ranging from 0 for waters that do not form any hydrogen bonds with non-
water molecules to about 6 for waters forming four high quality hydrogen bonds with 
excellent bond length and bond angle geometry. 
 In order to classify the water molecules, its HINT score and Rank were combined 
to give a Relevance value.59 The Relevance of a water molecule is calculated using the 
weighed probability equation – 
   𝑷𝑨 =   𝑷𝑹 𝑾𝑹 + 𝟏 𝟐   +   𝑷𝑯 𝑾𝑯 + 𝟏 𝟐  𝑾𝑹 + 𝟏 𝟐   + 𝑾𝑯 + 𝟏 𝟐    (3) 
where, PA is the overall probability or the “Relevance” value for a water molecule, PR 
and PH are the percent probabilities for water conservation based on Rank and HINT 
score, and WR and WH are the weights for these probabilities, respectively. A water 
molecule at a protein interface with PA ≥ 50% is considered “conserved” water, meaning 
it would be present in ligand-bound complex. This water Relevance metric, although 
trained on protein-ligand complexes, was extended to protein-protein complexes in 
order to identify the waters contributing towards bridging interaction, as we showed 
earlier.61 
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 The Relevance value for interfacial waters in all test cases was calculated using 
the above described model. We propose that an interfacial water molecule that is 
involved in bridging interactions should be Relevant to both proteins. As previously 
used,61 our criteria for considering a water molecule to be “truly bridging” was a 
Relevance score of ≥ 0.25 with respect to both proteins (thus giving it a total value of ≥ 
0.5). With this definition, the HINT scores, Rank and Relevance scores for interfacial 
waters in every test case was calculated. 
 
4.2.3 Solvated Docking using ZDOCK – 
For the present study, ZDOCK v3.0.2 (that incorporates a 3D convolution library 
to improve its efficiency) was obtained from http://zdock.umassmed.edu/software/. A 
total of 100 solutions were generated for each receptor-ligand pair in the data set. Since 
bound-bound docking was performed, a seed integer was specified for randomization of 
the starting coordinates for ligand structures. Also, rotational sampling was set to dense, 
which means the rotational search was performed in 6° steps. The receptor protein 
coordinates were fixed, preventing its rotation or switching with ligand during execution.  
 Using these parameters, two different docking protocols were evaluated on every 
case in the data-set of 15 protein-protein complexes:  
1. Unsolvated Docking: Standard rigid-body docking, absence of interfacial 
water molecules. 
2. Solvated Docking: Rigid-body docking, explicit inclusion of “bridging” water 
molecules identified using the HINT-based water Relevance metric. 
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For solvated docking, the interfacial bridging water molecules identified were added to 
the receptor file, and considered as a part of the protein. Since the ZDOCK 
program is not parameterized to include explicit waters in its algorithm, the ACE type, 
atom radius and atom charge for each water molecule was manually updated in the 
input file.  
 The ZDOCK output file provides information regarding the rotation and 
translation for the ligand with respect to its initial positioning. The protein-protein 
complex file was generated for each prediction; hydrogens were added and subjected to 
minimization under the Tripos force field (1000 iterations, 0.01 kcal mol-1 Å-1 gradient, 
Gasteiger-Hückel charges).  
 HINT interaction scores for unsolvated docking were calculated between the 
receptor protein and ligand protein for each prediction. In the case of solvated docking, 
the water molecules at the interface were first optimized using the water-optimization 
algorithm, as described earlier, followed by the HINT interaction score calculation that 
accounts for contributions from interfacial waters. For the purpose of comparison, the 
HINT scores were normalized with respect to the top HINT score for each case. The 
HINT scores for each prediction were represented as a fraction of top HINT score for 
each individual test case. The predictions were then ranked based on their scaled HINT 
scores. 
 
4.2.4 The Assessment Protocol – 
 A standard CAPRI assessment criteria was used to evaluate the predictions 
against the target crystallographic structures.29 A number of different characteristics of 
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predicted complexes were evaluated – not just the root mean square deviations 
(interfacial and ligand), but also the identification of correct residue-residue contact pairs, 
which is extremely important for inhibitor design. Figure 4.1 and 4.2 shows the 
schematic illustration of the three different parameters used to assess the quality of the 
predictions.  
Residue-Residue Contact Pairs (fnat) – Residues on either protein at the interface were 
considered to be in contact if any of their atoms were within 5 Å of each other. The total 
number of residue-residue contact pairs was calculated for the target structure 
(crystallographic complex structure) and for each prediction using SYBYL v8.1. ‘fnat’, 
defined as the fraction of number of native/correct contacts identified in the predicted 
complex structure with respect to the target structure, was then computed.  
Ligand Root Mean Square Deviation (l-RMSD) and Interface Root Mean Square 
Deviation (i-RMSD) – Two more parameters were calculated to evaluate the 3D fit 
between the predicted complexes and target structures. The global geometric fit was 
calculated by computing the l-RMSD, which is defined as the RMSD of the ligand 
backbone atoms in the predicted complexes versus the target structure, after 
superimposing the receptor protein. The fit within the interfacial region was quantified by 
calculating the i-RMSD, defined as the RMSD of the backbone atoms of all interfacial 
residues of predicted complexes versus target structure. For this calculation, interfacial 
residues were defined as those within 10 Å of the partner molecule. The interfacial 
residues were identified using SYBYL v8.1 and the l-RMSD and i-RMSD calculations 
were performed using the McLachlan algorithm73 as implemented in the program ProFit 
(Martin, A. C. R. and Porter, C. T., http://www.bioinf.org.uk/software/profit/). 
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The predictions were classified into four categories – incorrect models, acceptable 
models (*), medium-accuracy models (**) and high-quality models (***) based on the 
acceptance criteria shown in Table 4.3.  
Average Hit Count – A prediction with medium-accuracy or better (** or ***) was 
considered a “hit”. An average hit count was calculated for the top N predictions for both 
unsolvated and solvated docking protocols. 
Weighted Score – For the purpose of giving quantitative measures to the success of the 
two docking protocols, a weighted-scored was calculated for each test case by giving a 
value of 0, 1, 2, or 3 to the incorrect, acceptable, medium and high accuracy predictions 
within top N models ranked based on HINT scores, respectively. 
Statistical Analysis – All the statistical analysis were performed at the level of 
significance α = 0.05 using the software JMP v10.74  
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Figure 4.1 – Schematic illustration of residue-residue contact pairs. A receptor residue 
is considered to be in contact with a ligand residue if any of its atoms were within 5 Å of 
each other. fnat is the fraction of native/correct residue-residue contact pairs identified 
in a prediction. 
 
 
 
 
Figure 4.2 – Schematic illustration of ligand and interface RMSDs. l-RMSD is the 
RMSD of ligand backbone atoms between prediction and target structure, after 
superimposing receptor atoms. i-RMSD is the RMSD of interfacial residues, those within 
10 Å of partner molecule. 
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Table 4.2 – Predicted model quality classification criteria29 
Model Quality Criteria 
Incorrect fnat < 0.1 OR (l-RMSD > 10.0 Å AND i-RMSD > 4.0 Å) 
Acceptable (*) (fnat ≥ 0.1 AND fnat < 0.3) AND (l-RMSD ≤ 10.0 Å OR i-RMSD ≤ 4.0 Å) 
 OR 
 fnat ≥ 0.3 AND l-RMSD > 5.0 Å AND i-RMSD > 2.0 Å 
Medium (**) (fnat ≥ 0.3 AND fnat < 0.5) AND (l-RMSD ≤ 5.0 Å OR i-RMSD ≤ 2.0 Å) 
 OR 
 fnat ≥ 0.5 AND l-RMSD > 1.0 Å AND i-RMSD > 1.0 Å 
High (***) fnat ≥ 0.5 AND (l-RMSD ≤ 1.0 Å OR i-RMSD ≤ 1.0 Å) 
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4.3 Results 
 
4.3.1 Data Set  
 The protein-protein docking benchmark, developed by Weng’s group,68 
comprises a total of 176 cases that are classified into three classes based on the extent 
of conformational change at the interface upon complex formation – rigid body cases 
(123), medium difficulty cases (29) and difficult cases (24). The high-resolution (< 2.0 Å) 
subset of 42 complexes chosen from the data set contains cases from all the three 
classes defined by Weng and also represents a good sampling of the protein interface 
sizes,75 with change in accessible surface areas (ΔASA) on complex formation ranging 
from 808 to 3347 Å2.68 A complete hydropathic analysis of the protein-protein interface 
for each test case was performed using HINT. Only those water molecules that were 
relevant to both proteins, the so-called “Relevance 2” waters or “Bridging” waters, were 
retained with their protein-protein complexes, while those that were relevant to just one 
protein or neither were ignored for the present study. 12 out of 42 cases did not show 
the presence of any bridging waters and were removed from the data set. HINT 
interaction scores were now calculated, using the same parameters as described before, 
now taking into account the contribution of bridging waters. Table 4.2 lists the set of 
randomly selected 15 protein-protein complexes used for this study, along with their 
PDB ID, crystallographic resolution, chain IDs of receptor protein and ligand protein, the 
total numbers of interfacial waters and relevance-2/bridging waters, and their HINT 
interaction scores calculated with and without accounting for bridging waters. 
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Table 4.3 – Solvated protein-protein docking data set 
# PDB ID Resolution 
Chain ID 
Rec/Lig 
Water HINT Score 
Interfacial 
Bridging 
HOH 
Without HOH 
Accounting for 
Bridging HOH 
1 1avx 1.90 A/B 8 2 2122.30 2364.61 
2 1clv 2.00 A/I 30 8 -167.35 2319.10 
3 1dqj 2.00 AB/C 17 7 1786.58 2863.55 
4 1fle 1.90 E/I 12 1 1063.10 1035.44 
5 1iqd 2.00 AB/C 25 6 2011.56 2589.28 
6 1jiw 1.74 P/I 29 3 -2855.97 -1540.40 
7 1jps 1.85 HL/T 8 3 1172.06 1458.27 
8 1klu 1.93 AB/D 8 3 1249.55 1585.62 
9 1pxv 1.80 A/C 24 5 450.66 2509.35 
10 1r0r 1.10 E/I 27 6 -1361.36 -496.70 
11 1r8s 1.46 E/A 24 5 118.12 1974.93 
12 1wej 1.80 HL/F 10 6 1847.78 2735.49 
13 1zhh 1.94 A/B 32 10 -411.06 2223.41 
14 2hqs 1.50 A/H 46 7 -420.71 1523.90 
15 2sic 1.80 E/I 17 1 -1.08 159.11 
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4.3.2 ZDOCK – A rigid body docking program  
 ZDOCK uses the Fast Fourier Transform (FFT) algorithm to find the 3D structure 
of a protein complex, starting from structures of individual components, by optimizing 
three parameters – shape complementarity, electrostatics and desolvation free 
energy.76 Each individual protein file is first parsed through the mark_sur program that 
calculates the amount of accessible surface area (ASA) of each atom using a water 
probe and marks the atom type based on its atomic contact energy (ACE).77 This is 
followed by a search in the 3D translational space using a FFT approach with the ligand 
protein, the smaller of the two, rotated in either 15° or 6° steps resulting in a total of 
3,600 or 54,000 angles, respectively. The top scoring translation is retained for each 
angle. Each receptor-ligand complex is scored using physical and biochemical 
properties: i) pair-wise shape complementarity (PSC) that is composed of a favorable 
term coming from number of atoms pairs between receptor and ligand protein within a 
cutoff distance and a penalty term for number of overlapping grid points; ii) an 
electrostatic energy term that correlates the electric potential generated by receptor with 
the charges of ligand; and iii) desolvation free energy term calculated based on atomic 
contact energies.76  
 
4.3.3 HINT scores predict correct geometry  
 As previously mentioned, HINT scores have been successfully correlated to the 
free energy of interaction in case of protein-ligand systems. The use of HINT scoring 
function in distinguishing active molecules from inactive ones is well documented. The 
first key question that must be answered before building protein-protein docking 
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algorithms based on HINT scoring is whether that function accurately predicts geometry. 
To test this, we performed a rigid-body docking on the data set of 15 high-resolution 
protein-protein complexes (crystallographic resolution ≤ 2.0 Å). The coordinates of the 
individual partners were obtained from the complex structure, and 100 predictions for 
each test case were generated using ZDOCK (the unsolvated protocol). Intermolecular 
interaction score for each prediction was calculated using the HINT, followed by ranking 
them based on their scaled HINT scores. The accuracy of each prediction was 
evaluated using the standard CAPRI criteria by calculating three parameters – the fnat 
value, the l-RMSD and i-RMSD. Predictions were classified as incorrect, acceptable-
accuracy, medium-accuracy and high-accuracy models according to the cut-offs 
described in Table 4.3. 
A prediction with high fnat value (close to 1) indicates correct identification of the 
interface. Figure 4.3 shows a plot of fnat values vs scaled HINT score for all predictions 
(n = 1500). A significant positive linear correlation was observed between the scaled 
HINT scores and fnat values (r = 0.307, p < 0.0001). That is, predictions with high 
scaled HINT scores have fnat values close to 1 and those with lower scaled-HINT 
scores have fnat values close to 0. We also checked the fnat values of top 10 and 
lowest 10 HINT-ranked predictions for each test case. A total of n = 92 out of 150 (61%) 
of the top 10 ranked predictions have a fnat value of ≥ 0.3 (one of the criteria for 
medium accuracy, or better); with 10 out of 15 (67%) top ranked predictions having a 
value of > 0.5 (high accuracy criteria) (Figure 4.4a). Also, a total of n = 112 out of 150 
(75%) of the lowest 10 ranked predictions have a fnat value of < 0.3; with 12 out of the 
15 (80%) lowest ranked predictions having a fnat value of < 0.1 (incorrect prediction) 
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(Figure 4.4b). In addition, out of all the predictions with fnat value of 0, i.e. for all 
predictions where not a single native residue-residue contact was identified, a total of n 
= 622 out of 691 predictions (90%) have a scaled HINT score of < 0.5. In general, high 
HINT-ranked predictions have fnat values close to 1 and vice versa – indicating the 
utility of HINT scores as an effective filter for pose selection. 
 
4.3.4 Unsolvated Docking vs Solvated Docking –  
 Despite the progress made in the development of protein-protein docking 
programs, most predictions still lack considerable accuracy due to the complexity of the 
problem. When compared to docking small molecules into a pocket, there are many 
more degrees of freedom involved in bringing two proteins together. One of the most 
critical factors that influence the assembly of proteins – water, is almost always ignored. 
We believe that a protein-protein docking approach that explicitly accounts for interfacial 
waters, correct ionization states of residue side-chains and extensive flexibility during 
both the search and score stages will generate more accurate models. 
To test the first of these, Relevant interfacial waters, i.e., “bridging” waters, were 
identified for the 15 protein-protein complexes in the data-set using the HINT Relevance 
Metric, and a rigid-body solvated docking was performed by forcing ZDOCK to include 
“bridging” waters as atoms in the receptor protein. 100 solutions were generated for 
every test case. The interfacial waters in every prediction were optimized for their 
correct orientation using the HINT-based water-optimization algorithm. HINT interaction 
scores were then calculated taking into account the energetic contribution of these  
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Figure 4.3 – Scatterplot showing positive linear correlation between scaled HINT Scores and fnat values of all predictions 
for each test case (n = 1500) (r = 0.307, p < 0.0001).  
Predictions with high HINT scores have fnat values close to 1, and vice versa – indicating the ability of HINT to identify 
correct poses. For clarity purposes, points with scaled HINT scores below -1.5 are not shown. 
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Figure 4.4 – Scatterplot of fnat vs scaled HINT scores for top 10 and lowest 10 
predictions. 
 
(A) Scatterplot of fnat values vs scaled HINT scores for top 10 predictions of every test 
case (n = 150). More than 60% of all top 10 predictions (92 out of 150) have fnat values 
corresponding to medium accuracy or better models. The points shown in red are the 
top predictions; 10 out of 15 have fnat values of > 0.5 – corresponding to high accuracy 
prediction. 
(B) Scatterplot of fnat values vs Scaled HINT scores for the lowest 10 predictions of 
every test case (n = 150). 75% of all lowest 10 predictions (112 out of 150) have fnat 
values corresponding to acceptable or incorrect models. The points shown in red are 
the lowest ranked predictions; 12 out of 15 have fnat values < 0.1 – corresponding to 
incorrect prediction.  
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waters, and the predictions were ranked based on their scaled HINT scores. The 
accuracy of the predictions was evaluated according to the standard CAPRI criteria 
(Table 4.3), by computing three parameters – the fnat value, l-RMSD and i-RMSD; and 
classified as incorrect, acceptable-accuracy, medium-accuracy and high-accuracy 
models. 
 Two measures are calculated to compare the overall performance of unsolvated 
and solvated docking over the entire data-set – average hit-count and weighted-score. 
A prediction of medium accuracy or better was considered a hit and an average hit-
count was calculated for the top N predictions. Also, every prediction was given a score 
of 0, 1, 2 or 3 for incorrect, acceptable, medium or high accuracy, respectively. A total 
weighted-score was calculated for the top N predictions of each test case. 
 Table 4.4 shows the hit-count for the top N predictions in case of unsolvated and 
solvated docking. As it can be seen, solvated docking performs better overall than 
unsolvated docking in terms of average hit-count. Especially in the top 10 predictions, 
which are of more importance compared to lower ranked predictions, there was 
significant improvement in the hit-count for each test case (paired t-test, p < 0.05) 
(Figure 4.5), with an overall improvement of 24.72 % (7.40 for solvated docking, 
compared to 5.93 for unsolvated docking) in the average hit-count. On comparing the 
average hit-count for the top, top 10, top 25, top 50 and top 100 predictions, a 
significant improvement (paired t-test, p < 0.05) was observed in the number of hits 
generated for solvated docking (Table 4.5, Figure 4.6). 
Table 4.6 shows the weighted-score for the top N predictions in the cases of 
unsolvated and solvated docking. As can be seen, solvated docking performs better 
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overall than unsolvated docking in terms of the quality of predictions. There was a 
statistically significant improvement in the weighted-score for the top 10 predictions of 
each test case (paired t-test, p < 0.05) (Figure 4.7), with an overall improvement of 
22.94 % in the average weighted-score (17.87 for solvated docking, compared to 14.53 
for unsolvated docking). Similar to the average hit-count, the average weighed-score for 
top, top 10, top 25, top 50 and top 100 predictions showed statistically significant 
improvement (paired t-test, p < 0.05) for solvated docking (Table 4.7, Figure 4.8). When 
the number of high-accuracy predictions was compared (Table 4.8), similar 
improvements were observed. Most notable was the improvement seen in the success 
rate for the top ranked prediction: while the top prediction was a high-accuracy model 
for just n = 2 out of 15 (13%) test cases for unsolvated docking, the top prediction was a 
high-accuracy model for n = 6 out of 15 (40%) test cases for solvated docking. For the 
top ranked model, the quality of the prediction improved from incorrect/medium 
accuracy to high-accuracy for n = 5 out of total 15 (33%) test cases. 
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Table 4.4 – Hit-count for top N predictions for different docking protocols 
PDB ID 
  Unsolvated Docking   Solvated Docking 
  Top 1 Top 10 Top 25 Top 50 Top 100   Top 1 Top 10 Top 25 Top 50 Top 100 
1avx   1 8 20 36 54   0 9 22 41 63 
1clv 
 
1 10 25 50 95 
 
1 10 25 50 99 
1dqj 
 
0 1 10 16 16 
 
0 8 19 31 32 
1fle 
 
1 5 5 5 5 
 
1 5 8 9 9 
1iqd 
 
1 10 25 50 76 
 
1 10 25 49 85 
1jiw 
 
0 4 15 25 32 
 
1 7 17 27 33 
1jps 
 
0 0 1 1 1 
 
0 2 2 2 2 
1klu 
 
1 2 2 2 2 
 
1 4 5 5 5 
1pxv 
 
1 10 25 49 59 
 
1 10 24 43 62 
1r0r 
 
0 0 0 0 13 
 
0 0 0 0 25 
1r8s 
 
1 10 24 48 96 
 
1 10 25 50 93 
1wej 
 
0 4 4 4 4 
 
1 10 11 11 11 
1zhh 
 
1 6 8 9 9 
 
1 7 16 20 20 
2hqs 
 
1 9 16 19 19 
 
1 9 16 18 18 
2sic  1 10 24 47 74  1 10 22 46 72 
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Table 4.5 – Comparison of average hit-count for different docking protocols 
  
Docking 
Protocol 
n 
(test-
cases) 
Top N Predictions 
  1 10 25 50 100 
        Total hit-count Unsolvated 15 10 89 204 361 555 
 
Solvated 15 11 111 237 402 629 
Difference 
  
1 22 33 41 74 
        Average hit-
count Unsolvated 
 
0.67 5.93 13.60 24.07 37.00 
 
Solvated 
 
0.73 7.40 15.80 26.80 41.93 
Difference 
  
0.07 1.47 2.20 2.73 4.93 
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Figure 4.5 a – Number of hits in the top N predictions in unsolvated and solvated docking 
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Figure 4.5 b – Difference in number of hits in the top N predictions in unsolvated and solvated docking for each test case. 
(Δ = Nsolvated – Nunsolvated).  
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Figure 4.6 – Comparison of average hit-count in top N predictions for unsolvated and 
solvated docking. 
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Table 4.6 – Weighted-score for top N predictions for different docking protocols 
PDB ID 
  Unsolvated Docking   Solvated Docking 
  Top 1 Top 10 Top 25 Top 50 Top 100   Top 1 Top 10 Top 25 Top 50 Top 100 
1avx   2 19 48 93 143   1 19 52 97 155 
1clv 
 
3 30 75 149 284 
 
3 30 75 150 296 
1dqj 
 
0 2 24 36 39 
 
0 18 43 69 72 
1fle 
 
2 14 14 14 15 
 
3 15 24 27 28 
1iqd 
 
2 23 59 112 170 
 
2 21 56 109 188 
1jiw 
 
0 10 37 63 79 
 
2 17 41 68 80 
1jps 
 
0 0 3 3 3 
 
0 4 4 4 4 
1klu 
 
3 6 6 6 6 
 
3 12 16 16 16 
1pxv 
 
2 21 51 101 122 
 
2 21 49 91 130 
1r0r 
 
0 0 0 0 37 
 
0 0 0 0 71 
1r8s 
 
2 20 49 97 196 
 
2 20 51 102 189 
1wej 
 
0 10 13 14 14 
 
3 26 32 35 36 
1zhh 
 
2 14 18 20 20 
 
2 14 33 41 41 
2hqs 
 
2 23 40 49 49 
 
3 23 40 45 45 
2sic  2 26 60 112 190  3 28 59 113 189 
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Table 4.7 – Comparison of average weighted-score for different docking protocols 
  
Docking 
Protocol 
n 
(test-
cases) 
Top N Predictions 
  1 10 25 50 100 
        Total weighted-score Unsolvated 15 22 218 497 869 1367 
 
Solvated 15 29 268 575 967 1540 
Difference 
  
7 50 78 98 173 
        Average weighted-
score 
Unsolvated 
 
1.47 14.53 33.13 57.93 91.13 
 
Solvated 
 
1.93 17.87 38.33 64.47 102.67 
Difference 
  
0.47 3.33 5.20 6.53 11.53 
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Figure 4.7 a – Weighted – Score for the top N predictions in unsolvated and solvated docking 
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Figure 4.7 b – Difference in weighted-score for top N predictions in unsolvated and solvated docking for each test case. 
(Δ = Ssolvated – Sunsolvated).  
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Figure 4.8 – Comparison of average weighted – score for top N predictions for 
unsolvated and solvated docking. 
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Table 4.8 – Count of high-accuracy (***) models in top N predictions 
PDB ID 
  Unsolvated Docking   Solvated Docking 
  Top 1 Top 10 Top 25 Top 50 Top 100   Top 1 Top 10 Top 25 Top 50 Top 100 
1avx   0 1 3 7 8   0 0 5 6 7 
1clv 
 
1 10 25 49 94 
 
1 10 25 50 98 
1dqj 
 
0 0 4 4 4 
 
0 2 5 7 7 
1fle 
 
0 4 4 4 4 
 
1 5 8 9 9 
1iqd 
 
0 3 9 12 16 
 
0 1 6 10 14 
1jiw 
 
0 0 4 9 9 
 
0 2 5 11 11 
1jps 
 
0 0 1 1 1 
 
0 0 0 0 0 
1klu 
 
1 2 2 2 2 
 
1 4 5 5 5 
1pxv 
 
0 1 1 3 3 
 
0 1 1 5 6 
1r0r 
 
0 0 0 0 11 
 
0 0 0 0 21 
1r8s 
 
0 0 0 0 3 
 
0 0 1 2 2 
1wej 
 
0 2 2 2 2 
 
1 6 6 6 6 
1zhh 
 
0 2 2 2 2 
 
0 0 1 1 1 
2hqs 
 
0 5 8 11 11 
 
1 5 8 9 9 
2sic  0 6 12 18 19  1 8 15 20 21 
Total 
 
2 36 77 124 189 
 
6 44 91 141 217 
Average  0.13 2.40 5.13 8.27 12.60  0.40 2.93 6.07 9.40 14.47 
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The comparison between the predictions obtained from both docking protocols 
show that there is a significant improvement in the total number of hits and the quality of 
predictions for solvated docking. This trend indicates that more accurate and reliable 
results are obtained when bridging interfacial waters are not ignored. 
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4.4 Discussion 
 
 Detailed analysis of protein-protein complexes has revealed that water molecules 
form hydrogen bonds with interfacial side-chains, mediating and stabilizing the 
biomolecular association. Most water molecules are not randomly trapped in the 
protein–protein interface, but are part of the recognition code facilitating interactions that 
are less favorable in its absence.78 However, most current docking programs only take 
into account the underlying physics of protein-protein interactions, ignoring the role of 
water molecules. The conformational search step of the docking process is generally 
performed in vacuum, not accounting for the presence of water molecules. Some 
docking algorithms incorporate a desolvation term in their scoring functions, implicitly 
accounting for water. This improves the ranking of docked predictions and subsequent 
identification of correct configuration.79 However, implicit treatment of waters introduces 
approximations and the description of energetics is coarser than explicit models.  
 In the current study, we demonstrated that water can be explicitly introduced into 
protein-protein docking protocols. Using HINT-based tools to identify Relevant bridging 
water molecules and incorporating them into the docking protocol improves the quality 
of predictions. Figure 4.9 shows the plot of i-RMSD vs scaled HINT scores for all 
predictions obtained by our solvated docking protocol, grouped based on quality. A total 
of n = 111 out of 150 (74%) top 10 predictions were of medium accuracy or better 
(Table 4.5); showing improvements in not only the number of hits, but also in scoring 
with high/medium accuracy models ranking much better than incorrect ones. 
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Figure 4.9 – Scatterplot of i-RMSD vs scaled HINT Scores for all predictions obtained from solvated docking, grouped 
based on their quality.  
On average, predictions of high/medium accuracy rank much better than the incorrect ones. 
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We can now illustrate how docking results improve when a solvated docking 
approach is applied, using as an example the anti-lysozyme antibody HyHEL-63 
complexed with hen egg white lysozyme HEL (test case # 3, PDB ID: 1dqj). The crystal 
structure of the complex has been determined at 2.0 Å resolution, with the presence of 
17 interfacial waters (within 4.0 Å of both molecules).80 The orientation of each water 
molecule was optimized using the HINT-based optimization algorithm, as described 
before. The relevance of these waters was determined using HINT Relevance metric, 
which identified 7 waters to be Relevant to both proteins forming bridging interactions 
with interfacial residues (Table 4.9, Figure 4.10). The individual proteins were separated 
from the complex structure and subsequently docked using both the unsolvated and 
solvated docking protocols; the 7 bridging waters were considered as a part of receptor 
protein for the latter. As described before, the predictions were ranked based on their 
HINT interaction scores and also evaluated for accuracy based on standard CAPRI 
criteria. 
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Table 4.9 – HINT Water Relevance Report for interfacial waters* in Anti-Lyzozyme Antibody HyHEL-63 – Lyzozyme HEL 
complex crystal structure (test case #3, PDB ID – 1dqj).  
Water # Monomer Name 
  Target One - Anti-Lyzozyme 
Antibody HyHEL-63 
  Target Two -Lyzozyme  
HEL    Chain A/B  Chain C 
  Rank Score Relevance   Rank Score Relevance 
1 HOH130 
 
4.19 68.60 0.65 
 
1.51 72.20 0.37 
2 HOH131 
 
1.26 122.40 0.39 
 
2.34 -314.10 -0.47 
3 HOH133 
 
2.74 124.60 0.56 
 
2.78 -36.50 0.39 
4 HOH134 
 
1.03 -5.70 0.25 
 
2.58 -218.80 -0.24 
5 HOH138 
 
1.42 -58.90 0.21 
 
3.59 -195.60 -0.19 
6 HOH140 
 
0.00 -64.00 -0.04 
 
2.21 196.70 0.57 
7 HOH141 
 
2.50 48.70 0.45 
 
1.32 16.80 0.30 
8 HOH143 
 
1.44 117.60 0.41 
 
3.92 48.20 0.62 
9 HOH146 
 
0.90 -42.40 0.20 
 
1.20 272.00 0.44 
10 HOH152 
 
1.03 -43.40 0.22 
 
1.14 121.50 0.36 
11 HOH182 
 
2.40 123.30 0.52 
 
1.32 29.50 0.31 
12 HOH222 
 
3.00 270.70 0.71 
 
2.85 113.00 0.55 
13 HOH243 
 
1.02 -78.60 0.19 
 
1.08 116.60 0.35 
14 HOH263 
 
1.13 60.30 0.32 
 
0.00 -153.80 -0.07 
15 HOH327 
 
0.96 7.00 0.24 
 
0.93 42.50 0.27 
16 HOH335 
 
1.03 166.90 0.34 
 
0.00 -79.10 -0.04 
17 HOH388   1.11 43.70 0.30   0.92 36.50 0.26 
*Relevant/bridging waters (having relevance ≥ 0.25 for both proteins) are shown in bold.
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Figure 4.10 – (Top) Crystal Structure of Anti-Lysozyme Antibody HyHEL-63 (green) – 
Lysozyme HEL (cyan) complex (PDB ID: 1dqj). The image shows the presence of 
Relevant interfacial waters (red spheres). (Bottom) Detailed view of the interface 
showing bridging interactions of Relevant waters with residues on both proteins. 
Image prepared using PyMOL.81 
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In the case of unsolvated docking, a total of n = 16 out of 100 (proportion = 0.16) 
predictions were of medium accuracy or better (Table 4.4), with just one prediction of 
medium accuracy (rank = 10) within the top 10. Clustering the top 10 predictions 
showed three different poses for the ligand proteins – Cluster 1 consisting of n = 5 
predictions (rank – 1, 2, 3, 4, 8) was an incorrect pose; Cluster 2 consisting of n = 4 
predictions (rank – 5, 6, 7, 9) was also an incorrect pose; Cluster 3 consisting of n = 1 
prediction (rank – 10) was a medium accuracy pose (Table 4.10). Solvated docking, on 
the other hand, resulted in n = 32 (proportion = 0.32) predictions of medium accuracy or 
better (Table 4.4). More notable was the improvement in the accuracy of the top 10 
predictions. Clustering showed two different poses – Cluster 1 consisting of n = 2 
predictions (rank – 1, 3) was an incorrect pose; while Cluster 2 consisting of the 
remaining n = 8 predictions was the native-like pose, with 6 predictions of medium 
accuracy and 2 predictions (rank – 7, 8) of high-accuracy (Table 4.11)  
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Table 4.10 – Unsolvated docking results for HyHEL-63 – HEL complex 
Prediction HINT Score 
Scaled 
HINT 
Score 
Rank i-RMSD l-RMSD fnat Cluster/ Pose 
Model 
Quality Hit 
model 1 4805.926 1.000 1 8.549 11.004 0.127 1 - n 
model 2 4355.065 0.906 2 9.864 12.264 0.113 1 - n 
model 3 4236.699 0.882 3 9.806 12.167 0.127 1 - n 
model 4 4124.475 0.858 4 8.835 11.374 0.127 1 - n 
model 5 4115.901 0.856 5 7.954 12.733 0.028 2 - n 
model 6 4105.278 0.854 6 8.256 13.208 0.028 2 - n 
model 7 4036.962 0.840 7 8.388 13.442 0.028 2 - n 
model 8 3880.502 0.807 8 9.573 12.326 0.141 1 - n 
model 9 3835.744 0.798 9 8.235 13.061 0.014 2 - n 
model 10 3796.472 0.790 10 1.716 2.321 0.915 3 ** y 
Top 10 predictions, ranked based on their HINT scores. i-RMSD, l-RMSD and fnat values calculated against the complex 
crystal structure. Three clusters/poses for the ligand protein (within 2.0 Å of each other) were seen within the top 10 
models, as indicated by the number. Asterisks in the model quality column correspond to CAPRI quality criteria – high 
accuracy (***), medium accuracy (**), acceptable (*) and incorrect (-). Hit – a prediction with medium accuracy or better. 
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Table 4.11 – Solvated docking results for HyHEL-63 – HEL complex 
Prediction HINT Score 
Scaled 
HINT 
Score 
Rank i-RMSD l-RMSD fnat Cluster/ Pose 
Model 
Quality Hit 
model 1 6098.512 1.000 1 6.436 7.036 0 1 - n 
model 2 5327.556 0.874 2 1.617 2.223 0.944 2 ** y 
model 3 5045.993 0.827 3 7.194 7.474 0 1 - n 
model 4 4982.928 0.817 4 1.497 1.208 0.986 2 ** y 
model 5 4855.246 0.796 5 1.079 1.305 0.958 2 ** y 
model 6 4852.371 0.796 6 1.049 2.931 0.761 2 ** y 
model 7 4774.186 0.783 7 0.948 1.717 0.901 2 *** y 
model 8 4715.043 0.773 8 0.899 0.640 0.958 2 *** y 
model 9 4638.276 0.761 9 2.480 2.463 0.873 2 ** y 
model 10 4634.395 0.760 10 1.414 3.055 0.775 2 ** y 
Top 10 predictions, ranked based on their HINT scores. i-RMSD, l-RMSD and fnat values calculated against the complex 
crystal structure. Two clusters/poses for the ligand protein (within 2.0 Å of each other) were seen within the top 10 models, 
as indicated by the number. Asterisks in the model quality column correspond to CAPRI quality criteria – high accuracy 
(***), medium accuracy (**), acceptable (*) and incorrect (-). Hit – a prediction with medium accuracy or better. 
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These improvements in the solvated docking results can be attributed to the 
presence of water molecules that change the physical and chemical properties of the 
receptor protein interface. For instance, water HOH143 is involved in bridging 
interactions between B/Tyr58 of HyHEL-63 (receptor protein) and C/Val99 and 
C/Asp101 of HEL (ligand protein), as seen in the crystal structure (Figure 4.11). In 
unsolvated docking, because of the absence of an explicit water molecule near B/Tyr58, 
the region is occupied by residues of ligand protein – C/Gly22 in cluster 1 and C/Gln57 
in cluster 2, forming direct polar interactions with the Tyr –OH group and resulting in 
non-native like predictions. For cluster 3, a native like prediction with medium accuracy 
was generated, although the interaction between B/Tyr58 and C/Val99 is not observed 
(Figure 4.12). But when docking is performed using the solvated docking protocol, the 
presence of water HOH143 molecule results in better shape and hydropathic 
complementarity with the ligand surface and thereby leads to more accurate native-like 
predictions – cluster 2 retaining the water-mediated interaction between B/Tyr58 and 
C/Val99, as seen in the crystal structure. (Figure 4.13) 
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Figure 4.11 – Bridging interactions formed by Relevant interfacial water HOH 143 with 
Tyr58 of HyHEL-63 (receptor protein, green surface) and Val99 and Asp101 of HEL 
(ligand protein, cyan surface) observed in the crystal structure of the complex (PDB ID: 
1dqj). Image prepared using PyMOL. 
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Figure 4.12 – Unsolvated docking results for HyHEL-63 – HEL complex.  
The left panel for each cluster shows the overlay of predicted ligand pose (cyan 
cartoon) with the crystal structure (red cartoon). Only cluster 3 (n = 1 prediction) was a 
medium-accuracy native-like prediction. The right panel focuses on the interactions of 
B/Tyr58 with ligand residues. For cluster 1 and cluster 2, native residue-residue 
contacts are not retained, corresponding to incorrect predictions. 
Image prepared using PyMOL. 
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Figure 4.13 – Solvated docking results for HyHEL-63 – HEL complex.  
The left panel for each cluster shows the overlay of predicted ligand pose (cyan 
cartoon) with the crystal structure (red cartoon). Majority of top 10 predictions (n = 8) 
were native-like predictions. 
The right panel focuses on the bridging interactions of HOH143 with receptor and ligand 
residues. For cluster 1, non-native like prediction was generated showing water-
mediated interaction between B/Tyr58 and C/Lys116. For cluster 2 (that consists of 
majority of top 10 predictions, n = 8), native water-mediated residue-residue contacts 
are retained, with B/Tyr58 showing water-mediated hydrogen-bonding network with 
C/Val99 and C/Asp101. 
Image prepared using PyMOL. 
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Such results indicate that our solvated docking protocol, which utilizes HINT-
based tools, can be successfully used for improving protein-protein docking results. A 
significant improvement in the quality of top predictions indicates that HINT scoring 
function can effectively discriminate between poses and suggests that scoring can be 
improved when waters are explicitly accounted for.  
Even so, this approach is woefully crude because water is represented as only a 
single atom during the search stage and does not really reproduce its chemical 
properties. It is only during the scoring stage, when protons are added and water 
molecules are optimized, that the complete set of properties for the waters are 
incorporated. Since the HINT scoring function has shown to effectively identify native-
like poses from incorrect ones, even greater improvements can be expected if we can 
introduce HINT scoring in the conformational space search to ascertain the viability of a 
particular pose. This will result in more accurate predictions to proceed to the 
subsequent refinement and scoring stages, overall improving the success rate of the 
docking algorithm. 
Our current study focused on understanding the direct influence of interfacial 
water on the quality of structure prediction for protein-protein complexes. For this 
purpose, we performed a bound-bound docking, which means the starting structures of 
the proteins were obtained from the crystal structure of the bound complex. This 
eliminates two major issues that might result in incorrect predictions – protein flexibility 
associated with unbound docking and positions of Relevant water molecules. Ideally, 
we would like to like to start with unbound structures of the interacting partners and try 
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to predict the bound form, but this is a more difficult problem as it adds many more 
degrees of freedom to an already spectacularly under determined problem.  
The HINT forcefield and ancillary tools like the HINT water relevance metric, 
HINT-based computational titration and a novel HINT map based 3D refinement 
algorithm can be successfully used to model the hydropathic complementarity, the 
positions of Relevant interfacial waters, the correct ionization states of interfacial 
residues and interfacial protein flexibility, respectively. With appropriate refinements, a 
novel HINT-based docking approach can be designed that can accurately model 
protein-protein complexes. 
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4.5 Conclusion 
 Characterizing the nature of interactions between proteins that have not been 
experimentally co-crystallized requires a docking approach that can successfully predict 
the spatial conformation adopted in the complex. Interfacial waters contribute 
immensely to the kinetics and thermodynamics underlying protein-protein interactions. 
In this chapter, we have demonstrated the utility of HINT scoring and other 
computational tools based off it towards structural prediction of protein-protein 
complexes, by explicitly accounting for interfacial waters that are generally ignored in 
the current docking programs. We have shown that using hydropathic complementarity 
and not ignoring these Relevant waters in the modeling of protein complexes does show 
an statistically significant improvement in the quality of predictions generated by the 
docking algorithm. The analysis of illustrative example of anti-lysozyme – lysozyme 
complex revealed that certain binding modes that would otherwise be ranked higher can 
be eliminated by the steric presence of water molecules. Also, the explicit presence of 
interfacial waters may result in additional hydrogen bond interactions, improving the 
energy scores, and thereby ranking the correct binding modes higher.  
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CHAPTER 5 
CONCLUSIONS  
 
 
 
 Substantive progress is being made in the atomic and residue level 
understanding of biomolecular interactions. Computational tools that provide a 
quantitative assessment of the energetic contributions of individual interactions involved 
in molecular recognition have been extensively used in drug design and development 
process. An empirical HINT force field for quantifying non-covalent interactions, 
correlating with the ∆𝑮𝒊𝒏𝒕𝒆𝒓𝒂𝒄𝒕𝒊𝒐𝒏, has been developed by Kellogg and Abraham, based 
on experimental partition coefficient 𝐿𝑜𝑔𝑃!/! data.1 Being derived from an experimental 
thermodynamic parameter ( 𝐿𝑜𝑔𝑃!/! ), HINT is advantageous over other force 
fields/scoring functions because it accounts not only for the electrostatic, Coulombic, 
van der Waal’s and hydrophobic interactions, but also implicitly takes into consideration 
the contributions of entropy and solvation/desolvation processes towards the binding 
event. The implementation of HINT force field and various tools based off it has led to 
better understanding of the protein-ligand, protein-protein and protein-DNA 
associations.2-4 In this dissertation, we have discussed the use of HINT force field in 
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molecular modeling studies for novel anticancer and antiviral targets, as well as in 
developing a novel solvated protein-protein docking protocol. 
 In our efforts to gain structural insights into the isoform selectivity of a 
thiazolidine-2,4-dione analog (K145) towards Sphingosine kinase 2, an anti-cancer 
target, we successfully built structural models of both isoforms of sphingosine kinase 
(SphK1 and SphK2) using the crystal structure of a kinase of bacterial origin as the 
template. This was followed by molecular docking of the ligand in the sphingosine-
binding domains of both kinases. The analysis of proposed binding modes using HINT 
force field suggested that K145 binds more favorably to SphK2, but not SphK1, 
consistent with the biochemical assay results. We understand that the protein models 
and ligand binding modes have not been experimentally validated, and therefore should 
be used with caution. However, in absence of a crystallographic structure, the models 
can be used as hypothesis generator for future lead optimization and compound design 
efforts towards developing thiazolidine-based inhibitors as anti-cancer agents.5 
 The structural modeling of Human Cytomegalovirus (HCMV) Alkaline Nuclease 
(AN) UL98 has also been discussed in the dissertation. A similar homology-based 
modeling of UL98 AN was performed, using the crystal structure of a homologous 
exonuclease from another herpesvirus as the template, in order to identify active-site 
residues involved in its nucleolytic activity that are very important for viral replication. 
Again, hydropathic analysis of the protein-DNA complex using HINT force field identified 
the key residues: R164, S252, D254, E278 and K280 that showed significant 
interactions with 5’ end of DNA, to be important for its exo- and/or endo- nuclease 
activity. Mutagenesis studies were performed to validate the model, with alanine 
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substitutions abolishing activity. The results confirm the utility of the model in 
representing the active site region of UL98 AN.6  The protein-DNA complex model was 
then used to build a pharmacophore model complimentary to the protein active site, to 
virtually screen the NCI database of ~250,000 compounds. Molecular docking and 
subsequent scoring (using HINT force field) of the hits, yielded a number of novel 
interesting compounds, which have the potential to bind at UL98 AN active site and 
inhibit it. Top 15 compounds have been obtained from the vendor and are currently 
being evaluated experimentally. The use of an experimentally validated protein model 
and HINT scoring for identifying top hits, gives us confidence that our approach might 
result in identification of novel antiviral agents. 
 Finally, we have addressed the issue of explicit solvent accounting in protein-
protein docking algorithms. Several studies, using HINT based tools, have shown the 
importance of water molecules at interfaces, in mediating and stabilizing 
biomacromolecular associations.7-10 Majority of the current protein-protein docking 
approaches only implicitly incorporate the effects of solvent by introducing the 
desolvations terms in their scoring functions, which might be one of the reason for 
considerable lack in prediction accuracy. We hypothesize that docking algorithms that 
explicitly account for water at interface with yield more native-like models. On a data-set 
of 15 protein-protein complex crystal structures, we identified those waters that showed 
bridging interactions between both interacting partners, using the HINT Water 
Relevance Metric. We developed a solvated docking protocol – wherein the relevant 
waters were forced to be a part of one of the two proteins, followed by rigid-body 
docking using ZDOCK,11 and ranking the predictions using HINT energy scores. The 
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predictions were checked for accuracy using the standard CAPRI criteria.12 Comparing 
the results of solvated docking approach with a traditional unsolvated one, we have 
shown considerable improvement in the quality of predictions obtained. Our 
implementation of HINT based tools to the docking protocol is still at the simplest level, 
with complete chemical properties of waters being utilized only at the scoring stage. 
Even so, our study shows promise. It is safe to say that we can expect considerably 
higher prediction accuracy with further attempts to optimize the protein-protein docking 
algorithms by incorporating not just hydropathic complementarity, but also explicit 
solvent accounting, correct interfacial residue ionization states, and interfacial side-
chain flexibility. This study is just a beginning of the ultimate goal of our lab – to develop 
a protein-protein docking algorithm based on HINT tools. 
 To summarize, the overall goal of this multidisciplinary work was the application 
of HINT force field and HINT-based tools to different aspects of molecular modeling – 
from structural modeling of novel anticancer and antiviral targets, to explicit solvent 
accounting in a protein-protein docking approach. The results of this research will 
provide the scientific community with additional knowledge to better predict and model 
biomacromolecular structures.  
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APPENDIX A.1 
 
 
Clustal X default color scheme 
 
Each residue in the alignment is assigned a color if the amino acid profile of the 
alignment at that position meets the minimum criteria specific for the residue type. 
 
 
 
 
 
Residue at 
position 
Color {Threshold, Residue group} 
A,I,L,M,F,M,V Blue {+60%, WLVIMAFCHP) 
R,K Red {+60%, KR}, {+80%, KRQ} 
N Green {+50%, N}, {+85%, NY} 
C Blue {+60%, WLVIMAFCHP) 
C Pink {100%, C} 
Q Green {+60%, KR}, {+50%, QE}, {+85%, QEKR} 
E Magenta {+60%, KR}, {+50%, QE}, {+85%, EQD} 
D Magenta {+60%, KR}, {+85%, KRQ}, {+50%, ED} 
G Orange {+0%, G} 
H,Y Cyan {+60%, WLVIMAFCHP}, {+85%, WYACPQFHILMV} 
P Yellow {+0%, P} 
S,T Green {+60%, WLVIMAFCHP}, {+50%, TS}, {+85%, ST} 
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